WO2015029068A1 - Aryl naphthyl methanone oxime(s) and process for preparation thereof - Google Patents

Aryl naphthyl methanone oxime(s) and process for preparation thereof Download PDF

Info

Publication number
WO2015029068A1
WO2015029068A1 PCT/IN2014/000556 IN2014000556W WO2015029068A1 WO 2015029068 A1 WO2015029068 A1 WO 2015029068A1 IN 2014000556 W IN2014000556 W IN 2014000556W WO 2015029068 A1 WO2015029068 A1 WO 2015029068A1
Authority
WO
WIPO (PCT)
Prior art keywords
methanone
naphthalen
oxime
compound
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2014/000556
Other languages
French (fr)
Other versions
WO2015029068A4 (en
Inventor
Sabyasachi SANYAL
Atul Kumar
Naibedya Chattopadhyay
Jawahar LAL
Arun Kumar TRIVEDI
Dipak DATTA
Srikanta Kumar Rath
Tahseen AKHTAR
Shailendra Kumar Dhar DWIVEDI
Manisha YADAV
Bandana CHAKRAVARTI
Abhishek Kumar Singh
Jay Sharan MISHRA
Nidhi Singh
Anil Kumar Tripathi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council of Scientific and Industrial Research CSIR
Original Assignee
Council of Scientific and Industrial Research CSIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council of Scientific and Industrial Research CSIR filed Critical Council of Scientific and Industrial Research CSIR
Priority to US14/915,194 priority Critical patent/US9994515B2/en
Priority to EP14786724.6A priority patent/EP3039010B1/en
Publication of WO2015029068A1 publication Critical patent/WO2015029068A1/en
Publication of WO2015029068A4 publication Critical patent/WO2015029068A4/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/60—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/02—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/26—Thiols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Definitions

  • the present invention relates to substituted aryl naphthyl methanone oxime (s) of formula I, useful for treatment of cancer, more particularly for treatment of chronic myelogenous leukemia, acute myelogenous leukemia, lymphoma, multiple myeloma, solid tumor forming cell-lines including breast cancer, endometrial cancer, colon cancer, prostate cancer and also for killing of drug resistant cancer stem cells.
  • the present invention also relates to a process for preparation of substituted aryl naphthyl methanone oxime (s).
  • Cancer or malignant neoplasia is a broad group of various diseases characterized by uncontrolled and abnormal growth of cells. It can arise in any organ of the body such as lungs, breast, ovary, intestine etc. The cancerous cells can invade nearby tissues and can spread through the blood stream and lymphatic system to other parts of the body and this process is termed as metastasis. The unchecked growth of cancer results in the death of the host, as a rule, in a few months to few years from the first appearance of symptoms depending to a certain extent upon the site of origin.
  • HDAC histone deacetylase
  • DNMT Deoxyribose nucleic acid methyl transferase
  • (-)-Epigallocatechin 3-gallate (EGCG) is the most intriguing accepted product that exhibit DNMT inhibitory activity though their beneficial anticancer activity may fade due to intercede of its multiple biological effects [Lambert, J. D.; Sang, S.; Yang, C. S. Chem Res Toxicol (2007), 20, (4), 583-5.].
  • Bexarotene is retinoic acid mimetic DNMT inhibitor and is in preclinical stages for the treatment of cutaneous T-cell lymphoma [Qu, L.; Tang, X. Cancer Chemother Pharmacol (2010) 65, (2), 201-5.].
  • tyrosine kinase inhibitors have proved successful in treatment of various kinds of cancers including chronic myelogenous leukemia (CML) and acute myelogenous leukemia (AML) as well as solid tumors.
  • CML chronic myelogenous leukemia
  • AML acute myelogenous leukemia
  • Imatinib an inhibitor of BCR-ABL, a constitutively active tyrosine kinase found in CML patients with Philadelphia chromosome (an abnormal translocation of chromosome 9 and 22 creating a fusion between break-point cluster gene (BCR) and ABL kinase) has been the first choice drug for BCR-ABL-positive CML since 2001.
  • BCR break-point cluster gene
  • ABL ABL kinase
  • Nilotinib has relatively favorable safety profile over imatinib as first line tyrosine kinase inhibitor for the treatment of leukemia [Goldman, J. M.; Marin, D. Oncology (Willis ton Park). (2012) Oct;26(10):901-7].
  • Dual SRC/BCR-ABL tyrosine kinase inhibitor dasatinib has been approved for use in patients with chronic myelogenous leukemia (CML), especially in imatinib resistant cases [Santos, F. P.; Kantarjian, H.; Quintas- Cardama, A.; Cortes, J. Cancer J (2011) 17, (6), 465-76.].
  • dasatinib also exhibits limited success rate in imatinib resistant patients and there is occurrence of dasatinib-resistance [Soverini, S.; et al. Haematologica. (2007) Mar;92(3):401-4] .
  • Dual BCR-ABL/Lyn tyrosine kinase inhibitors like bafetinib or bosutinib have shown strong efficacy in leukemia and solid tumors [Santos, F. P.; Kantarjian, H.; Quintas-Cardama, A.; Cortes, J. Cancer J (2011) 17, (6), 465-76., Amsberg, K.G.; Brummendorf, T. H.
  • Inhibitors of type III receptor tyrosine kinase family members including platelet derived growth factor receptors and FMS like tyrosine kinase 3, like tandutinib, sorafenib have been found effective in both leukemia and a number of solid tumors [DeAngelo, D. J.; Stone, R. M.; Heaney, M. L.; Nimer, S. D.; Paquette, R. L.; Klisovic, R. B.; Caligiuri, M. A.; Cooper, M. R.; Lecerf, J. M.; Karol, M. D.; Sheng, S.; Holford, N.; Curtin, P. T.; Druker, B.
  • Dovitinib a multiple tyrosine kinase inhibitor that also inhibits topoisomerases I and II have been shown to be effective in multiple cancer types [Hasinoff, B. B.; Wu, X.; Nitiss, J. L.; Kanagasabai, R.; Yalowich, J. C. Biochem Pharmacol (2012) 84, (12), 1617-26].
  • Cyclin dependent kinase (CDK) inhibitors alone or in combination are also being actively pursued for treatment of both leukemia and solid tumors; Flavopiridol, a synthetic flavonoid inhibitor of CDKs, arrests cell division and causes apoptosis in non-small lung cancer cells and is currently under phase I clinical trial for combination treatment of CML patients with imatinib [Bose, P.; Perkins, E. B.; Honeycut, C; Wellons, M. D.; Stefan, T.; Jacobberger, J. W.; Kontopodis, E.; Beumer, J. H.; Egorin, M. J.; Imamura, C.
  • PD 0332991 is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity [Leonard, J. P.; LaCasce, A. S.; Smith, M. R.; Noy, A.; Chirieac, L. R.; Rodig, S. J.; Yu, J.
  • CDK pyridopyrimidine-derived cyclin-dependent kinase
  • Imatinib resistance in BCR-ABL-dependent CML can be divided into two types :a.
  • BCR-ABL dependent b. BCR-ABL independent. BCR-ABL-dependent resistance can occur due to mutations in the BCR-ABL protein which prevents its binding to imatinib, therefore rendering this protein insensitive to the drug (Pricl, S.;
  • T315I point mutation which occurs at the 315 th amino acid of the ABL kinase, where a threonine moiety is substituted by an isoleucine moiety eliminates an essential oxygen molecule that is critical for hydrogen bonding between BCR-ABL.
  • BCR-ABL has been shown to be insensitive to not only imatinib but also to a number of BCR-ABL inhibitors such as dasatinib and bosutinib [(Pricl, S.; Fermeglia, M.; Ferrone, M.; Tamborini, E. Mol Cancer Ther. (2005) 4(8): 1 167-74).
  • BCR- ABL-independent imatinib resistance can occur due a number of mechanisms including drug efflux by P-glycoprotein or multi drug resistance group of transporter proteins, defects in drug import in the intracellular milieu or activation of alternate signaling pathway such as activation of src family of kinases which have been implicated in imatinib signaling as well as locking imatinib in an active conformation which is incapable of binding to imatinib (Nestal de Moraes, G.; Souza, P. S.; Costas, F. C; Vasconcelos, F. C; Reis, F.R.; Maia, R. C. Leuk Res Treatment. (2012) ;2012:671702.).
  • cancer stem cells These cells are termed as “cancer stem cells” (CSC) and they typically harbour some stem cell markers on the cell surface and are refractory to drug treatments. Such CSCs are also evident in all cancer types including solid tumors and are responsible for relapse. In colon cancer cells these CSCs harbour CD133 in the cell surface (O'Brien, C.A.; Pollett, A.; Gallinger, S.; Dick, J. E. Nature. (2007) 445(7123): 106-10.).
  • chemotherapy Treatment of cancer by the use of natural, synthetic, or biologic chemical agents to reverse, suppress, or prevent the process of carcinogenesis is termed as chemotherapy.
  • effective implementation of this strategy requires cytotoxicity in not only the malignant cells but also in the cancer stem cells to prevent relapse of cancer following chemotherapy.
  • the main object of the present invention is to provide a substituted aryl naphthyl methanone oxime(s) or a pharmaceutically acceptable salt thereof.
  • Another object of the present invention is to provide a pharmaceutical composition containing substituted aryl naphthyl methanone oxime(s) and a pharmaceutically acceptable carrier or a diluent thereof.
  • Yet another object of the present invention is to provide a process for preparation of substituted aryl naphthyl methanone oxime (s).
  • Still another object of the present invention is to provide a_substituted aryl naphthyl methanone oxime (s) for treatment of hematological malignancy, particularly their use in treatment of leukemia, acute leukemia, lymphoma, multiple myeloma, solid tumors and cancer stem cells.
  • s aryl naphthyl methanone oxime
  • Yet another object of the present invention is to provide a compound which obviates the drawback of currently available drugs.
  • Still another object of the present invention is to provide a compound which causes robust apoptosis in existing drug resistant cancer samples.
  • Yet another object of the present invention is to provide a compound that induces differentiation in blast cells which is indicative of restoring normal blood cell functions.
  • Still another object of the present invention is to provide a compound which is also efficacious in solid tumor forming cell-lines including, breast, prostate, colon and endometrial cancers.
  • Yet another object of the present invention is to provide a compound which is efficacious in killing drug resistant cancer stem cells.
  • the present invention provides substituted aryl naphthyl methanone oxime(s) of formula (I) and their pharmaceutically acceptable salts thereof.
  • R 2 H, halogen, alkyl, alkoxy, hydroxy, nilro
  • R 3 H, alkyl, alkoxy, nilro, halogen
  • R 4 hydrogen, akyl group ( ⁇ :,-3 ⁇ 4), alkylamino group (c,-c e ). cyclic or open chain amines
  • R 5 hydrogen, alkyl group (Ci-cg), alkylepoxy.alkylh droxyamino group
  • the compounds are selected from the group consisting of :
  • the compound is for use in the treatment of cancer and killing of drug resistant cancer stem cells.
  • the cancer is selected from the group consisting of blood cancer, leukemia, lymphoma and multiple myeloma.
  • the starting compound 3 used for the preparation of compound of general formula I have been synthesized by our previously reported procedure.( Srivastava, N.; Sangita; Ray, S.; Singh, M. M.; Dwivedi, A.; Kumar, A., Bioorg Med Chem (2004), 12, (5), 1011-21).
  • R 1 H, halogen, alkyl, alkoxy, nitro
  • R 2 H, halogen, alkyl, alkoxy, hydroxy, nitro
  • R 3 H, alkyl, alkoxy, nitro, halogen
  • R 4 hydrogen, alkyl group (c ce), alkylamlno group ( ⁇ :,- ⁇ 3 ⁇ 4). cyclic or open chain amines
  • R 1 H, halogen, alkyl, alkoxy, nitro
  • R J H, halogen, alkyl, alkoxy, hydroxy, nitro
  • R 3 H, alkyl. alkoxy, nitro, halogen
  • R s alkyl group (ci-ce), alkylepoxy.alkylhydroxyamino group
  • the process for the preparation of compound of general formula I comprising of reacting a substituted phenylnaphthalen-l-yl-methanone oxime derivative (4) of formula I (scheme 2) with an aminoalkyl chloride, alkyl chloride, alkylepoxychloride, cyclic or open chain amino chloride, alkylhydroxyaminochloride, alkylacetachloride or dihaloalkane (scheme 2) in the presence of a suitable base (defined in scheme 2) at reflux to furnish the compound 5, 6, 7 & 8 of formula I (scheme 2).
  • the base is selected from the group consisting of K 2 C0 3 , CsC0 3 , KOH and NaH.
  • the solvent is selected from the group consisting of dry DMF, acetone and THF.
  • the pharmaceutically acceptable salts of the compound of general formula I is selected from the group consisting of hydrochlorides, citrates, oxalates, fumarates, malates and tartrates.
  • R 1 , R 2 H, halogen, alkyl, alkoxy, nitro Formula I
  • R 5 H, alkyl, alkoxy, nitro, halogen
  • R alkyl, aryl
  • R 8 alky group, dialkyl groups, cycloalkane
  • the process for the preparation of compound of general formula I comprising of reacting 5p of formula I with potassium tertiary butoxide and cyclic or open chain amine to produce 5q of formula I. (Scheme 3).
  • the process for the preparation of compound of general formula I comprising of reacting 4a with alkylbromoacetate and the base used is Sodium hydride giving the product 5p of formula I
  • the reactions to furnish the compound of formula I are carried out without any catalyst.
  • a method for treatment of cancer in a subject comprising, administring to a subject in need thereof an effective amount of a compound of formula 1.
  • the compound is for use in the treatment of leukemia.
  • the compound is for use in suppression of BCR-ABL activity in CML thereof.
  • the compound is for use in suppression of c-SRC activity in imatinib-resistance in CML thereof.
  • the compound is for use in inducing apoptosis in imatinib-resistant CML cells.
  • the compound is for use in inducing of apoptosis and differentiation in AML cells.
  • the compound is for use in inducing megakaryocyte differentiation in K562 cells and inducing differentiation in blast cells of erythroleukemia or increasing platelet amount.
  • the compound is for use in exhibiting cancer-specific cytotoxicity in ER-positive or ER-negative breast cancer cells, prostate cancer cells, utemine adenocarcinoma and colon cancer cells.
  • the compound is for use in selective cytotoxicity towards cancer stem cells such as but not limited to CD133+ colon cancer stem cells.
  • the representative compounds of formula I and its salts thereof are used for the treatment of solid tumors and hematological malignancy, more particularly their use in treatment of leukemia, acute leukemia, lymphoma and multiple myeloma.
  • the pharmaceutical composition comprising an effective amount of a compound of formula I optionally along with a pharmaceutically acceptable carrier or diluents.
  • the compound is for use as anticancer agent and for treatment of hematological malignancy such as their use in treatment of leukemia, acute leukemia, lymphoma and multiple myeloma and as well as in solid tumors.
  • Fig. 1 CentANS induces apoptotic cell death in K562 and HL-60 cells
  • Fig. 2 CentANS induces G0/G1 growth arrest in K562 and HL-60 cells.
  • Fig. 3 Centans induces dephosphorylation of BCR-ABL and SRC protooncogene.
  • Fig. 4 Centans induces megakaryocyte differentiation in K562 Cells
  • Fig. 5 Centans induces Granulocytic/monocytic differentiation in HL-60 cells.
  • Fig. 6 Centans induces apoptotic cell death in breast cancer cells
  • Fig. 7 Centans induces dephosphorylation of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (Her2).
  • EGFR epidermal growth factor receptor
  • Her2 human epidermal growth factor receptor 2
  • Fig. 8 Centans causes reduction of tumor volume in vivo.
  • Fig. 9 Centans reduces CD133+ colon cancer stem cells.
  • Centans Abbreviation used for compounds based on the IUPAC name of the compound, prefixed with Cent; a Central Drug Research Institute signature.
  • CML Chronic myelogenous leukemia
  • AML Acute myelogenous leukemia
  • PBMC Peripheral blood mononuclear cells
  • ABL Abelson murine leukemia viral oncogene homolog 1
  • BCR-ABL a fusion protein of BCR and ABL
  • eIF4E Eukaryotic translation initiation factor 4E
  • GATA-2 GATA binding protein 2
  • the present invention provides the process for preparation of substituted aryl naphthyl methanone oximes of general formula (I) and their derivatives, salts, pharmaceutical composition thereof and their use in treatment of chronic myelogenous leukemia, acute myelogenous leukemia, lymphoma, multiple myeloma, breast cancer, endometrial cancer prostate cancer and colon cancer as subject in need thereof.
  • the present invention provides substituted aryl naphthyl methanone oxime (s) of formula (I), for use in the treatment of hematological malignancy, particularly for use in treatment of leukemia, acute leukemia, lymphoma and multiple myeloma and solid tumors such as breast cancer, endometrial cancer, prostate cancer and colon cancer.
  • R' H, halogen, alky), alkoxy, nlro
  • R 2 H, halogen, alkyl, alkoxy, hydroxy, nilro
  • R 3 H, alkyl, alkoxy, nitro, halogen
  • R 4 hydrogen, alkyl group (c,- ⁇ 3 ⁇ 4). alkylamlno group (c,-c e ), cyclic or open chain amines
  • R* hydrogen, alkyl group (ci ). alkylepoxy.alkythydroxyamlno group
  • This invention also relates to a process for the preparation of Substituted Aryl naphthyl methanone cixime (s). Reacting the substituted Naphthalene- 1-carboxylic acid (1) and suitably substituted phenol or thiophenol (2) in the presence of PPA at 90 °C to yield compound 3b.
  • Formula II [Atul Kumar, S. R. Pathak, Pervez Ahmad, S. Ray, P. Tewari, A. K. Srivastava Bioorganic & Medicinal Chemistry Letters 16 (2006) 2719-2723].
  • R 1 H, halogen, alkyl, alkoxy, nitro
  • R 2 H. halogen, alky(, alkoxy, hydroxy, nitro
  • R 3 H, alkyl, alkoxy, nitro, halogen
  • R 4 hydrogen, alkyl group ( ⁇ ,- ⁇ 3 ⁇ 4), alkyiamino group (ct-c e ), cyclic or open chain amines
  • Method A Into a 50 ml round bottom flask, 4-(methylthiophenyl)(naphthalen-l- yl)methanone oxime (1 mmole, 293 mg), 2-chloro-N,N-diethylethanamine hydrochloride (1.2 mmole, 205 mg), baked K 2 C0 3 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K 2 C0 was filtered off and washed with acetone (2x10 ml).
  • Method B Into a 50 ml round bottom flask, 4-(methylthiophenyl)(naphthalen-l- yl)methanone oxime (1 mmole, 293 mg), 2-chloro-N,N-diethylethanamine hydrochloride ( 1.2 mmole, 205 mg), Cs 2 C0 3 (5 mmole) and dry DMF (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 5 hours. The reaction was followed by TLC monitoring. After completion of the reaction, filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (62.6%).
  • EXAMPLE 8 Synthesis of (4-(methylthio)phenyl)(naphthaIen-l-yl)methanone 0-2-(diisopropylamino)ethyI oxime (Compound 5e).
  • Method B Into a 50 ml round bottom flask, 4-(methylthio)phenyl (naphthalen-1- yl)methanone oxime (I mmole, 293 mg), (2-Chloro-propyl)-dimethyl-amine hydrochloride (1.2 mmole, 189.6 mg), baked 2CO3 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refiuxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K 2 C0 3 was filtered off and washed with acetone (2x10 ml).
  • EXAMPLE 14 Synthesis of (4-(methylthio)phenyl)(aaphthalen-l-yl)methanone 0-2-(diethylamino)ethyl oxime tartrate (Compound 5k) Procedure for tartrate salt formation: tartric acid, lmmole/ lmmole of compound, (95.66 mg) and (4-, (methylthio)phenyl)(naphthalen- 1 -yl)methanone 0-2-(diethylamino)ethyl oxime (250 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly and kept in refrigerator for overnight after adding dry diethyl ether.
  • EXAMPLE 21 Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methanone O- 2-(piperidin-l-yl)ethyl oxime oxalate (Compound 6a).
  • EXAMPLE 22 Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methanone O- 2-(pyrrolidin-l-yl)ethyl oxime oxalate (Compound 6b).
  • EXAMPLE 25 Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methanone O- 2-(diisopropylamino)ethyl oxime oxalate (Compound 6e).
  • the product obtained was oily so a salt of the compound was prepared.
  • EXAMPLE 26 Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methanone O- l-(dimethylamino)propan-2-yl oxime oxalate (Compound 6f).
  • EXAMPLE 27 Synthesis of (4-methoxyphenyI)(naphthalen-l-yl)methanone O- 2-(azepan-l-yl)ethyl oxime oxalate (Compound 6g).
  • Example 36 Synthesis of (4-methoxyphenyI)(naphthaIen-l-yl)methanone 0-3- (2-ethylhexylamino)propyl oxime (Compound 7e).
  • Table-1 IC50 ( ⁇ ) values of compounds in K562, HL60 and NIH3T3 cell lines as tested using MTT assay after 48h treatment. Results were calculated from three independent experiments performed in triplicate. Compounds with IC50 more than 15 ⁇ were considered inactive.
  • test compound To consider a molecule as a candidate compound in cancer drug therapy, the test compound must have specific cytotoxicity towards the cancer cells without affecting normal cell growth. Therefore, all active compounds were assessed for toxicity in non-cancer cell-lines: mouse fibroblast cell line (NIH3T3) and monkey kidney epithelial cells (Vero). 5d and 5m exhibited much higher IC50 values in the normal cells compared to leukemia cells. Therefore, based on safety index (IC50/CC50), 5d [Centans; based on IUPAC name prefixed with Central Drug Research Institute's signature (Cent)] was selected as a lead compound.
  • safety index IC50/CC50
  • Table 2 ICso of Active compounds in Leukemia and normal cell lines. Results were calculated from three independent experiments performed in triplicates.
  • Centans The efficacy of Centans in comparison to marketed drugs imatinib and dasatinib were determined in K562 and HL-60 cells that were used as examples of CML and AML respectively. As shown in table 3, Centans exhibited a much lower IC50 in comparison to both imatinib and dasatinib, indicating its higher efficacy.
  • Table 3 IC50 of Centans, imatinib and dasatinib in K562 and HL60 cell lines after 48h of treatment. Following 48h treatment of indicated cell lines with Centans, imatinib or dasatinib (10 point dose response) MTT assays were performed and IC- 50 for the compounds were determined. Results were calculated from three independent experiments performed in triplicates.
  • Centans shows higher efficacy than imatinib and dasatinib in peripheral blood mononuclear cells (PBMC) isolated from CML patients.
  • PBMC peripheral blood mononuclear cells
  • BCR-ABL +ve imatinib sensitive, imatinib resistant CML
  • Centans showed most robust cytotoxic effect in PBMCs from imatinib-resistant CML patients (72%) compared to imatinib (40%) and dasatinib (59%). Centans also showed higher cytotoxicity than imatinib or dasatinib in PBMCs from freshly diagnosed or imatinib sensitive patients, while all three drugs showed comparative activity on PBMCs from healthy controls.
  • Table 4 PBMCs isolated from indicated groups of BCR-ABL-positive CML patients or healthy individuals were treated with 1 ⁇ Centans, imatinib or dasatinib for 48h and the cytotoxicity was determined by MTT assay in triplicates. Data represents % cell death. Centans showed better efficacy than both imatinib and dasatinib in all the groups, but this efficacy was highest in imatinib-resistant patient samples (p ⁇ 0.01).
  • Centans induces cell death in PBMCs from patients with BCR-ABL mutations including multi-drug resistant T315I mutation with higher efficacy than imatinib and dasatinib.
  • Centans-induced cell-death in K562 and HL-60 is apoptotic in nature.
  • phosphatidylserine exposure (Annexine V/ PI; Flow cytometry) was performed in K562 and HL-60 cell-lines. As apparent form Figure 1 , treatment with Centans caused a robust and dose-dependent increase in phosphatidylserine exposure, which reached 5 fold over vehicle with 5 ⁇ ANS in K562 and about 3 fold in HL-60.
  • Centans induces Apoptosis in K562 and HL-60 cells.
  • a and B Centans increases phosphatidylserine exposure- K562(A) and HL-60 (B) cells were treated with vehicle (DMSO) or Centans (dissolved in DMSO) at indicated concentrations for 24 h and phosphatidylserine exposure was assessed by flow cytometry using the FLl-H channel (Annexin-V) and FL2-H channel (PI). Representative dot plots and relative apoptotic cell in the graph are shown.
  • C and D is the graphical representation of data pooled from three independent experiments. *P ⁇ 0.05, **P ⁇ 0.01 ***P ⁇ 0.001 compared to vehicle treated control. Centans induces G0/G1 growth arrest in K562 and HL-60 cells.
  • Fig 2 Centans induces Gl Growth arrest.
  • a and B Cell cycle analysis - Propidium iodide (PI) staining of K562 cells (A) and HL-60 cells (B) treated with vehicle (DMSO) or 0.5 ⁇ Centans, followed by flow cytometry analysis to find % distribution of cells in different phases of the cell cycle. Data has been shown as percent of total cells from data pooled from three independent experiments.
  • C and D mRNA expression of cell cycle regulatory factors- 562(C) or HL-60 (D) cells were treated with Vehicle or Centans, followed by mRNA isolation and cDNA preparation and quantitative real-time PCR (p21, p27 and cyclin Dl). Graphs reprented pooled data from three independent experiments.
  • Bcr-Abl Kinase activity of Bcr-Abl is the major cause of CML, and since Centans causes growth arrest and apoptosis in Bcr-Abl positive K562 cells, phosphorylation status of Bcr-Abl which is representative of its kinase activity was measured by immunoblotting. As shown in Fig 3 both imatinib and Centans dose dependently inhibited phosphorylation of BCR-ABL (pBCR-ABL) and its downstream substrates stat5 and Crkl, while eIF4E (used as a control gene unaffected by BCR-ABL signalling) remained unchanged.
  • Centans inhibits BCR-ABL signalling and SRC phosphorylation.
  • K562 Cells were treated with V (DMSO), 0.5 ⁇ , 1 ⁇ Centans or 1 ⁇ Imatinib for 48h and protein lysate prepared from these cells were used to detect the phosphorylation status of BCR-ABL, STAT-5, CRKL and vSRC-1 by western blotting.
  • ELF4E and ⁇ -actin were used as loading control.
  • Centans treated cells was stained with Wright- Giemsa stain.
  • Figure 4.A. clearly indicates that Centans is capable of inducing differentiation in K562 cells in a dose-dependent manner. After 3 day of incubation with 0.5 ⁇ of Centans, cells exhibited megakaryocyte morphology characterized by a sharp increase in nuclear-to-cytoplasm ratio, and multiple lobed nuclei, while the vehicle-treated cells displayed homogenous population of immature blast-like cell morphology (Fig. 4. A). This differentiation was much more pronounced at 12d, where mature megakaryocytes were visible (Fig. 4A).
  • CentANS induces Differentiation in K562 cells.
  • A Giemsa Staining- K562 cells treated with CentANS (0.5 ⁇ ) for 3, 6 and 12 days and were cytospinned on Microscopy slides and stained with Giemsa and May Grunwald solutions, slides were micro-photographed and used to detect change in nuclear morphology.
  • B Expression of differentiation Markers - 562 cells were treated with vehicle; V (DMSO) or centANS and mRNA from these cells were isolated and reverse transcribed. cDNA was used to measure the expression CD 10, GATA2, CD61, (megakaryocytic lineage markers) and CD36 (Erythroid lineage marker) by Quantitative Real time PCR, GAPDH was used as control. Data represents mean ⁇ SEM from three independent experiments; *P ⁇ 0.05, **P ⁇ 0.01, and ***P ⁇ 0.001 compared to control.
  • Centans induces granulocytic/monocytic differentiation in HL-60:
  • Fig. 5A (upper panel), morphological features of differentiation, such as condensation of nuclei and protrusion of cytoplasm, were clearly evident among the treated cells. This was further confirmed by nitro blue tetrazolium (NBT) reduction assay in HL-60 cells (NBT reduction is a hallmark of monocyte activity).
  • Fig. 5A (lower panel) depicts time-dependent reduction of NBT by Centans-treated cells.
  • Centans induces granulocytic/monocytic differentiation in HL-60 model of AML.
  • B. HL60 cells were treated with Vehicle (DMSO) or Centans as indicated in image, mRNA from these samples were isolated and reverse transcribed and these samples were used to measure the expression of CD1 lb GCSFR,and ⁇ / ⁇ & ⁇ by Quantitative realtime PCR, using GAPDH as normalizing control. Data presented as mean ⁇ SEM from three independent experiments; *P ⁇ 0.05, **P ⁇ 0.01, and ***P ⁇ 0.001 compared to vehicle treated control.
  • Centans and related series of compounds were evaluated in solid tumor cell-lines MCF-7 (estrogen receptor positive, non-metastatic breast tumor), MDA- MB-231 (estrogen receptor negative, metastatic breast tumor), DU-145 (prostrate tumor), Ishikawa (endometrial adenocarcinoma) cells by MTT assay following 24h treatment of indicated compounds.
  • MCF-7 estrogen receptor positive, non-metastatic breast tumor
  • MDA- MB-231 estrogen receptor negative, metastatic breast tumor
  • DU-145 prostrate tumor
  • Ishikawa endometrial adenocarcinoma
  • centans Efficacy of centans in colon cancer cell-lines were also assessed using sulphorhodamine B assay and as shown in table 7, centans exhibited robust cytotoxicity in four different colon cancer cell lines compared to the marketted drug for colon cancer 5-fluoro uracil (5-FU). Table 7. IC50 of Centans in colon cancer cell lines as determined Sulphorhodamine B (SRB) assay.
  • SRB Sulphorhodamine B
  • Centans induces apoptosis in MCF-7 and MDA-MB-231 cell-lines.
  • apoptosis was measured by flow cytometry using annexin V PI staining kit from Sigma according to manufacturer's instructions. A concentration-dependent increase in apoptotic cell population was observed upon treatment with Centans and the effect was stronger in MDA-MB231 than MCF-7 cells (Fig 6A and B).
  • Fig.6 Apoptosis induction by Centans in breast cancer cells.
  • Annexin V/PI staining of (A) MCF-7 and (B) MDA-MB231 cells were treated with vehicle (DMSO) or Centans at indicated concentrations for 24 h and DNA fragmentation was assessed by flow cytometry using the FLl-H channel (Annexin-V) and FL2-H channel (PI) of a Becton Dickinson FACS Calibur. Shown are representative dot plots. Quantification of flow cytometry data shown as percent of total cells (right panel). Data presented as mean ⁇ SEM from three independent experiments; * P ⁇ 0.05, ** P ⁇ 0.01, and " * P ⁇ 0.001 compared to control.
  • Centans inhibits EGFR and Her2 phosphorylation
  • Centans reduces tumor volume in mouse xenograft model:
  • Fig.8 Regression of xenograft tumor by Centans in athymic nude mice.
  • B Effect of Centans treatment on tumor morphology. Representative tumor sections from mice treated with vehicle or Centans (lemg.kg ' .day " ') for 25 days.
  • C Effect of Centans treatment on PCNA levels were analyzed by Western blotting from in tumors of vehicle or Centans treated mice. Data represent mean ⁇ S.E.M. ** P ⁇ 0.01 compared to vehicle-treated control.
  • centans showed cytotoxicity in drug resistant leukemic cells
  • the efficacy of centans in cancer stem cells was assessed.
  • Fig. 9 In vehicle (DMSO) treated control cells 15.30% cells were found to be CD133+ (value represents %CD133+ cells minus % cells in isotype control) and 24h treatment with 20uM centans reduced this population to 2.94% (5.79-2.85), while salinomycin the positive control at equivalent concentration reduced the CD 133+ population to 5.42% (5.91-0.49) and 5-FU had no effect.
  • Centans reduces CD 133+ colon cancer stem cells with a higher efficacy than salinomycin.
  • DLD1 colon cancer cells were treated with indicated compounds for 24h following which the CD 133+ population was assessed by flow cytometry using CD 133 antibody or relevant isotype control antibody (BD biosciences) in a Becton Dickinson FACS Calibur. Numbers in the dot plot represent % CD 133+ cells.
  • the present compound shows better efficacy than existing drugs imatinib and dasatinib both in leukemia cell-lines and patient samples.
  • the present compound causes robust apoptosis in imatinib resistant cancer samples.
  • the present compound induces cell death in broader range of leukemic cells than imatinib or dasatinib.
  • the present compound induces differentiation in blast cells which is indicative of restoring normal blood cell functions.
  • the present compound is also efficacious in solid tumor forming cell-lines including, breast, prostate and endometrial cancers.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to substituted aryl naphthyl methanone oximes of general formula (I), their process for preparation and their derivatives, salts, pharmaceutical composition thereof and their use in treatment of chronic myelogenous leukemia, acute myelogenous leukemia, lymphoma, multiple myeloma, solid tumor forming cell-lines including such as breast cancer, endometrial cancer colon cancer, prostate cancer and killing of drug resistant cancer stem cells, as subject in need thereof.

Description

ARYL NAPHTHYL METHANONE OXIME(S) AND PROCESS FOR
PREPARATION THEREOF
FIELD OF THE INVENTION
The present invention relates to substituted aryl naphthyl methanone oxime (s) of formula I, useful for treatment of cancer, more particularly for treatment of chronic myelogenous leukemia, acute myelogenous leukemia, lymphoma, multiple myeloma, solid tumor forming cell-lines including breast cancer, endometrial cancer, colon cancer, prostate cancer and also for killing of drug resistant cancer stem cells. The present invention also relates to a process for preparation of substituted aryl naphthyl methanone oxime (s).
BACKGROUND OF THE INVENTION
Cancer or malignant neoplasia is a broad group of various diseases characterized by uncontrolled and abnormal growth of cells. It can arise in any organ of the body such as lungs, breast, ovary, intestine etc. The cancerous cells can invade nearby tissues and can spread through the blood stream and lymphatic system to other parts of the body and this process is termed as metastasis. The unchecked growth of cancer results in the death of the host, as a rule, in a few months to few years from the first appearance of symptoms depending to a certain extent upon the site of origin.
The cancer of blood or bone marrow is called leukemia which is characterized by abnormal increase of immature white blood cells.Mainly three classes of agents have been most extensively studied in the search of chemical inducers of differentiation of leukemic cells viz. histone deacetylase (HDAC) inhibitors [Zini, R.; Norfo, R.; Ferrari, F.; Bianchi, E.; Salati, S.; Pennucci, V.; Sacchi, G.; Carboni, C; Ceccherelli, G. B.; Tagliafico, E.; Ferrari, S.; Manfredini, R. Exp Hematol (2012) 40, (12), 1043- 1054 e6], Deoxyribose nucleic acid methyl transferase (DNMT) inhibitors [Savickiene, J.; Treigyte, G.; Borutinskaite, V. V.; Navakauskiene, R. Cell Mol Biol Lett (2012) 17, (4), 501-25] and retinoic acid receptor agonists [Brown, G.; Hughes,
Figure imgf000004_0001
F) CYCLIN DEPENDENT KINASE INHIBITORS
Figure imgf000004_0002
flavopir!dol PO0332991 RO-330S
P. Leuk Res Treatment (2012), 939021]. (-)-Epigallocatechin 3-gallate (EGCG) is the most intriguing accepted product that exhibit DNMT inhibitory activity though their beneficial anticancer activity may fade due to intercede of its multiple biological effects [Lambert, J. D.; Sang, S.; Yang, C. S. Chem Res Toxicol (2007), 20, (4), 583-5.]. Bexarotene is retinoic acid mimetic DNMT inhibitor and is in preclinical stages for the treatment of cutaneous T-cell lymphoma [Qu, L.; Tang, X. Cancer Chemother Pharmacol (2010) 65, (2), 201-5.]. In addition, tyrosine kinase inhibitors have proved successful in treatment of various kinds of cancers including chronic myelogenous leukemia (CML) and acute myelogenous leukemia (AML) as well as solid tumors. Imatinib, an inhibitor of BCR-ABL, a constitutively active tyrosine kinase found in CML patients with Philadelphia chromosome (an abnormal translocation of chromosome 9 and 22 creating a fusion between break-point cluster gene (BCR) and ABL kinase) has been the first choice drug for BCR-ABL-positive CML since 2001. However, occurrence of frequent imatinib resistance in patients has necessitated the search for new chemical entities. Nilotinib has relatively favorable safety profile over imatinib as first line tyrosine kinase inhibitor for the treatment of leukemia [Goldman, J. M.; Marin, D. Oncology (Willis ton Park). (2012) Oct;26(10):901-7]. Dual SRC/BCR-ABL tyrosine kinase inhibitor dasatinib has been approved for use in patients with chronic myelogenous leukemia (CML), especially in imatinib resistant cases [Santos, F. P.; Kantarjian, H.; Quintas- Cardama, A.; Cortes, J. Cancer J (2011) 17, (6), 465-76.]. However, dasatinib also exhibits limited success rate in imatinib resistant patients and there is occurrence of dasatinib-resistance [Soverini, S.; et al. Haematologica. (2007) Mar;92(3):401-4] . Dual BCR-ABL/Lyn tyrosine kinase inhibitors like bafetinib or bosutinib have shown strong efficacy in leukemia and solid tumors [Santos, F. P.; Kantarjian, H.; Quintas-Cardama, A.; Cortes, J. Cancer J (2011) 17, (6), 465-76., Amsberg, K.G.; Brummendorf, T. H. Expert Rev anticancer ther (2012) 12, (9), 1 121-1 127., Daud, A. I.; Krishnamurthi, S. S.; Saleh, M. N.; Gitlitz, B. J.; Borad, M. J.; Gold, P. J.; Chiorean, E. G.; Springett, G. M.; Abbas, R.; Agarwal, S.; Bardy-Bouxin, N.; Hsyu, P. H.; Leip, E.; Turnbull, K.; Zacharchuk, C; Messersmith, W. A. Clin Cancer Res (201 1) 18, (4), 1092-1 100]. Inhibitors of type III receptor tyrosine kinase family members including platelet derived growth factor receptors and FMS like tyrosine kinase 3, like tandutinib, sorafenib have been found effective in both leukemia and a number of solid tumors [DeAngelo, D. J.; Stone, R. M.; Heaney, M. L.; Nimer, S. D.; Paquette, R. L.; Klisovic, R. B.; Caligiuri, M. A.; Cooper, M. R.; Lecerf, J. M.; Karol, M. D.; Sheng, S.; Holford, N.; Curtin, P. T.; Druker, B. J.; Heinrich, M. C. Blood (2006), 108, (12), 3674-81]. Dovitinib, a multiple tyrosine kinase inhibitor that also inhibits topoisomerases I and II have been shown to be effective in multiple cancer types [Hasinoff, B. B.; Wu, X.; Nitiss, J. L.; Kanagasabai, R.; Yalowich, J. C. Biochem Pharmacol (2012) 84, (12), 1617-26]. Efficacy of Cyclin dependent kinase (CDK) inhibitors alone or in combination are also being actively pursued for treatment of both leukemia and solid tumors; Flavopiridol, a synthetic flavonoid inhibitor of CDKs, arrests cell division and causes apoptosis in non-small lung cancer cells and is currently under phase I clinical trial for combination treatment of CML patients with imatinib [Bose, P.; Perkins, E. B.; Honeycut, C; Wellons, M. D.; Stefan, T.; Jacobberger, J. W.; Kontopodis, E.; Beumer, J. H.; Egorin, M. J.; Imamura, C. K.; Douglas Figg, W., Sr.; Karp, J. E.; oc, O. N.; Cooper, B. W.; Luger, S. M; Colevas, A. D.; Roberts, J. D.; Grant, S. Cancer Chemother Pharmacol (2012) 69, (6), 1657-67], PD 0332991 is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity [Leonard, J. P.; LaCasce, A. S.; Smith, M. R.; Noy, A.; Chirieac, L. R.; Rodig, S. J.; Yu, J. Q.; Vallabhajosula, S.; Schoder, H.; English, P.; Neuberg, D.S.; Martin, P.; Millenson, M. M.; Ely, S. A.; Courtney, R.; Shaik, N.; Wilner, K. D.; Randolph, S.; Van den Abbeele, A. D.; Chen-Kiang, S. Y.; Yap, J. T.; Shapiro, G. I. Blood (2012):119(20):4597-607] and RO-3306 reversibly arrests human cells at the G2/M border of the cell cycle [Aarts, M.; Sharpe, R.; Garcia- Murillas, I.; Gevensleben, H.; Hurd, M. S.; Shumway, S. D.; Toniatti, C; Ashworth, A.; Turner, N. C. Cancer Discov 2, (6), 524-39.].
Imatinib resistance in BCR-ABL-dependent CML can be divided into two types :a.
BCR-ABL dependent, b. BCR-ABL independent. BCR-ABL-dependent resistance can occur due to mutations in the BCR-ABL protein which prevents its binding to imatinib, therefore rendering this protein insensitive to the drug (Pricl, S.;
Fermeglia, M.; Ferrone, M.; Tamborini, E. Mol Cancer Ther. (2005) 4(8): 1167-74).
Among the reported mutations, T315I point mutation which occurs at the 315th amino acid of the ABL kinase, where a threonine moiety is substituted by an isoleucine moiety eliminates an essential oxygen molecule that is critical for hydrogen bonding between BCR-ABL. BCR-ABL has been shown to be insensitive to not only imatinib but also to a number of BCR-ABL inhibitors such as dasatinib and bosutinib [(Pricl, S.; Fermeglia, M.; Ferrone, M.; Tamborini, E. Mol Cancer Ther. (2005) 4(8): 1 167-74). Weisberg, E.; Manley, P.W.; Cowan-Jacob, S.W.; Hochhaus, A.; Griffin, J.D. Nat Rev Cancer. (2007) 7(5):345-56.] Only ponatinib has been shown to be effective against this mutation (O'Hare, T.; Deininger, M.W.; Eide, C.A.; Clackson, T.; Druker, B.J. Clin Cancer Res. (201 1) 17(2):212-21). BCR- ABL-independent imatinib resistance can occur due a number of mechanisms including drug efflux by P-glycoprotein or multi drug resistance group of transporter proteins, defects in drug import in the intracellular milieu or activation of alternate signaling pathway such as activation of src family of kinases which have been implicated in imatinib signaling as well as locking imatinib in an active conformation which is incapable of binding to imatinib (Nestal de Moraes, G.; Souza, P. S.; Costas, F. C; Vasconcelos, F. C; Reis, F.R.; Maia, R. C. Leuk Res Treatment. (2012) ;2012:671702.). In addition, it has been shown that even in imatinib sensitive cells where BCR-ABL activity is downregulated by imatinib an undifferentiated subpopulation of cells expressing the cluster of differentiation (CD) 34 (CD34; a member of the sialomucin group of transmembrane proteins ) but are CD38 negantive (CD34+ CD38-) are not killed by imatinib and these cells ultimately are responsible for relapse of leukemia (Corbin, A.S.; Agarwal, A.; Loriaux, M.; Cortes, J.; Deininger, M.W.; Druker, B.J. J Clin Invest. (201 1); 121(l):396- 09). These cells are termed as "cancer stem cells" (CSC) and they typically harbour some stem cell markers on the cell surface and are refractory to drug treatments. Such CSCs are also evident in all cancer types including solid tumors and are responsible for relapse. In colon cancer cells these CSCs harbour CD133 in the cell surface (O'Brien, C.A.; Pollett, A.; Gallinger, S.; Dick, J. E. Nature. (2007) 445(7123): 106-10.). Till date therapeutics for CSCs are not available and only salinomycin has been shown to be effective in killing these cells in vitro (Gupta, P.B.; Onder, T.T.; Jiang, G.; Tao, K.; Kuperwasser, C; Weinberg, R.A.; Lander, E. S. Cell. (2009) 138(4):645-59).
Treatment of cancer by the use of natural, synthetic, or biologic chemical agents to reverse, suppress, or prevent the process of carcinogenesis is termed as chemotherapy. Essentially, effective implementation of this strategy requires cytotoxicity in not only the malignant cells but also in the cancer stem cells to prevent relapse of cancer following chemotherapy.
OBJECTIVE OF THE INVENTION
The main object of the present invention is to provide a substituted aryl naphthyl methanone oxime(s) or a pharmaceutically acceptable salt thereof.
Another object of the present invention is to provide a pharmaceutical composition containing substituted aryl naphthyl methanone oxime(s) and a pharmaceutically acceptable carrier or a diluent thereof.
Yet another object of the present invention is to provide a process for preparation of substituted aryl naphthyl methanone oxime (s).
Still another object of the present invention is to provide a_substituted aryl naphthyl methanone oxime (s) for treatment of hematological malignancy, particularly their use in treatment of leukemia, acute leukemia, lymphoma, multiple myeloma, solid tumors and cancer stem cells.
Yet another object of the present invention is to provide a compound which obviates the drawback of currently available drugs.
Still another object of the present invention is to provide a compound which causes robust apoptosis in existing drug resistant cancer samples.
Yet another object of the present invention is to provide a compound that induces differentiation in blast cells which is indicative of restoring normal blood cell functions.
Still another object of the present invention is to provide a compound which is also efficacious in solid tumor forming cell-lines including, breast, prostate, colon and endometrial cancers.
Yet another object of the present invention is to provide a compound which is efficacious in killing drug resistant cancer stem cells. SUMMARY OF THE INVENTION
Accordingly, the present invention provides substituted aryl naphthyl methanone oxime(s) of formula (I) and their pharmaceutically acceptable salts thereof.
Figure imgf000009_0001
Formula I
1= H, halogen, alkyl, alkoxy, nitro
R2 = H, halogen, alkyl, alkoxy, hydroxy, nilro
R3 = H, alkyl, alkoxy, nilro, halogen
X = O. S
R4 = hydrogen, akyl group (<:,-¾), alkylamino group (c,-ce). cyclic or open chain amines
R5 = hydrogen, alkyl group (Ci-cg), alkylepoxy.alkylh droxyamino group
(ci-ce),alkylamlno group (ci-ce), cyclic or open chain amlnes.esler and amides derivatives
elected from the group consisting of
Figure imgf000009_0002
m = 1 , 2 , 3. 4 In another embodiment of the invention, the compounds are selected from the group consisting of :
I. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone oxime (4a),
2. (4-methoxyphenyl)(naphthalen-l-yl)methanone oxime (4b),
3. (4-hydroxyphenyl)(naphthalen-l-yl)methanone oxime (4c),
4. (4-(methylthio)phenyl)(naphthalen- 1 -yl)methanone 0-2-(piperidin- 1 -yl)ethyl oxime oxalate (5a),
5. (4-(methylthio)phenyl)(naphthalen- 1 -yl)methanone 0-2-(pyrrolidin- 1 -yl)ethyl oxime oxalate (5b),
6. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2-(dimethylamino)ethyl oxime oxalate (5c),
7. (4-(methylthio)phenyl)(naphthalen- 1 -yl)methanone 0-2-(diethylamino)ethyl oxime oxalate (5d),
8. (4-(methylthio)phenyl)(naphthalen- 1 -yl)methanone 0-2-(diisopropylamino)ethyl oxime (5e),
9. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone O-2-morpholinoethyl oxime (5f),
10. (4-(methylthio)phenyl)(naphthalen- 1 -yl)methanone O- 1 -(dimethylamino)propan- 2-yl oxime oxalate (5g),
I I. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2-(azepan-l-yl)ethyl oxime oxalate (5h),
12. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2-(diethylamino)ethyl oxime citrate (5i),
13. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2-(diethylamino)ethyl oxime fumarate (5j), 14. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2-(diethylamino)ethyl oxime tartrate (5k),
15. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2-(diethylamino)ethyl oxime (51),
16. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-3-(dimethylamino)propyl oxime oxalate (5m),
17. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone O-3-chloropropyl oxime (5n),
18. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone O-4-chlorobutyl oxime (5o), 19. Ethyl 2-((4-(methylthio)phenyl)(naphthalen-l-yl)methyleneaminooxy)acetate (5p),
20. N,N-diethyl-2-((4-(methylthio)phenyl)(naphthalen- 1 -yl)methyleneaminooxy) acetamide (5q),
21. (4-methoxyphenyl)(naphthalen-l-yl)methanone 0-2-(piperidin-l-yl)ethyl oxime oxalate (6a),
22. (4-methoxyphenyl)(naphthalen- 1 -yl)methanone 0-2-(pyrrolidin- 1 -yl)ethyl oxime oxalate (6b),
23. (4-methoxyphenyl)(naphthalen- 1 -yl)methanone 0-2-(dimethylamino)ethyl oxime oxalate (6c),
24. (4-methoxyphenyl)(naphthalen- 1 -yl)methanone 0-2-(diethylamino)ethyl oxime oxalate (6d),
25. (4-methoxyphenyl)(naphthalen- 1 -yl)methanone 0-2-(diisopropylamino)ethyl oxime oxalate (6e),
26. (4-methoxyphenyl)(naphthalen- 1 -yl)methanone O- 1 -(dimethylamino)propan-2- yl oxime oxalate (6f),
27. (4-methoxyphenyl)(naphthalen-l-yl)methanone 0-2-(azepan-l-yl)ethyl oxime oxalate (6g), 28. (4-methoxyphenyl)(naphthalen-l-yl)methanone O-2-morpholinoethyl oxime (6h),
29. (4-methoxyphenyl)(naphthalen-l-yl)methanone 0-3-(dimethylamino)propyl oxime oxalate (6i),
30. (4-methoxyphenyl)(naphthalen-l-yl)methanone O-3-chloropropyl oxime (6j),
31. (4-methoxyphenyl)(naphthalen- 1 -yl)methanone 0-3 -(piperidin- 1 -yl)propyl oxime (6k),
32. (4-(methylthio)phenyl)(naphthalen- 1 -yl)methanone 0-3 -(piperidin- 1 -yl)propyl oxime oxalate (7a),
33. (4-(methylthio)phenyl)(naphthalen- 1 -yl)methanone 0-3 -mo holinopropyl oxime (7b),
34. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-3-(4-methylpiperidin-l- yl)propyl oxime oxalate (7c),
35. (4-(methylthio)phenyl) (naphthalen-l-yl)methanone 0-3-(butyl(methyl)amino) propyl oxime (7d),
36. (4-methoxyphenyl)(naphthalen- 1 -yl)methanone 0-3-(2-ethylhexylamino)propyl oxime (7e),
37. (4-(methylthio)phenyl)(naphthalen- 1 -yl)methanone 0-4-(piperidin- 1 -yl)butyl oxime (8a),
38. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-4-(pyrrolidin-l-yl)butyl oxime (8b),
39. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-4-(phenethylamino)butyl oxime (8c),
40. (4-(methylthio)phenyl)(naphthalen- 1 -yl)methanoneO-4-(benzyl(ethyl) amino) butyl oxime (8d),
In another embodiment of the invention, the compound is for use in the treatment of cancer and killing of drug resistant cancer stem cells. In yet another embodiment of the invention, the cancer is selected from the group consisting of blood cancer, leukemia, lymphoma and multiple myeloma.
In another embodiment of the present invention the starting compound 3 used for the preparation of compound of general formula I have been synthesized by our previously reported procedure.( Srivastava, N.; Sangita; Ray, S.; Singh, M. M.; Dwivedi, A.; Kumar, A., Bioorg Med Chem (2004), 12, (5), 1011-21).
In another embodiment of the present invention the process for the preparation of compound of general formula I, the said process comprising of:
Reacting substituted phenylnaphthalen-l-yl-methanone (3) of formula II with hydroxylamine hydrochloride and dry pyridine in absolute ethanol to form substituted phenylnaphthalen-l-yl-methanone oxime (4) of formula I. (scheme 1).
Scheme-1
Figure imgf000013_0001
Formula II Formula I
(Compound 3) (compound 4)
R1 = H, halogen, alkyl, alkoxy, nitro
R2 = H, halogen, alkyl, alkoxy, hydroxy, nitro
R3= H, alkyl, alkoxy, nitro, halogen
X = O, S
R4= hydrogen, alkyl group (c ce), alkylamlno group (<:,-<¾). cyclic or open chain amines
Sc eme-1
Scheme-2 4 Cl-R5
(
Formula I compound 5, 6)
Figure imgf000014_0001
Formula I (compound 7, 8)
R1= H, halogen, alkyl, alkoxy, nitro
RJ = H, halogen, alkyl, alkoxy, hydroxy, nitro
R3 = H, alkyl. alkoxy, nitro, halogen
X = O, S, Y, Z = halogen, n= 1 ,2,3,4,5,6.
R4 * hydrogen, akyl group (c,-(¾), alkylamino group (c,-ca), cyclic or open chain amines
Rs = alkyl group (ci-ce), alkylepoxy.alkylhydroxyamino group
(ci-ce),alkylamino group (ci-ce), cyclic or open chain amines, alkyl ester and amides derivatives R6 = hydrogen, alkyl group (C1-03), alkylamino group (ci-C6>, cyclic or open chain amines R7 = alkyl group (c-|-ce), alkylamino group (ο,-Cg), cydic or open chain amines
Re / R" 7 ,
Figure imgf000014_0002
Figure imgf000014_0003
In another embodiment of the present invention the process for the preparation of compound of general formula I, the said process comprising of reacting a substituted phenylnaphthalen-l-yl-methanone oxime derivative (4) of formula I (scheme 2) with an aminoalkyl chloride, alkyl chloride, alkylepoxychloride, cyclic or open chain amino chloride, alkylhydroxyaminochloride, alkylacetachloride or dihaloalkane (scheme 2) in the presence of a suitable base (defined in scheme 2) at reflux to furnish the compound 5, 6, 7 & 8 of formula I (scheme 2).
In another embodiment of the present invention the base is selected from the group consisting of K2C03, CsC03, KOH and NaH.
In yet another embodiment the solvent is selected from the group consisting of dry DMF, acetone and THF.
In another embodiment of the present invention the pharmaceutically acceptable salts of the compound of general formula I is selected from the group consisting of hydrochlorides, citrates, oxalates, fumarates, malates and tartrates.
Scheme-3
Formula I K2CO Acetone_ Formula I
*" (Compound 5p)
(Compound 4ateS2co3/DMF
Figure imgf000016_0001
R1, R2 = H, halogen, alkyl, alkoxy, nitro Formula I
R3, R4 = H, halogen, alkyl, alkoxy, hydroxy, nitro (Compound 5q)
R5 = H, alkyl, alkoxy, nitro, halogen
X = o, s
Figure imgf000016_0002
m = 1 , 2 , 3, 4
R = alkyl, aryl
R8 = alky group, dialkyl groups, cycloalkane
Schme-3.
In another embodiment of the present invention the process for the preparation of compound of general formula I, the said process comprising of reacting 4a with alkylbromoacetate and the base used is Sodium hydride giving the product 5p of formula I
In another embodiment of the present invention the process for the preparation of compound of general formula I, the said process comprising of reacting 5p of formula I with potassium tertiary butoxide and cyclic or open chain amine to produce 5q of formula I. (Scheme 3). In another embodiment of the present invention the process for the preparation of compound of general formula I, the said process comprising of reacting 4a with alkylbromoacetate and the base used is Sodium hydride giving the product 5p of formula I
In another embodiment of the present invention the process for the preparation of compound of general formula I, the said process comprising of reacting 5p of formula I with potassium tertiary butoxide and cyclic or open chain amine to produce 5q of formula I. (Scheme 3).
HBr/AcOH
HBr/H20 NH2OH.HCI,
3b formula II Base ^
3c formula II 4c formula I
BBr3 dry ethanol
Pyridine. H CI
Scheme 4
In another embodiment of the present invention the process for the preparation of compound of general formula II, the said process comprising of:
Reacting substituted Methoxy-phenyl)-naphthalen-l-yl-methanone (3b) formula II with HBr/acetic acid, HBr/H20, BBr3 or pyridine hydrochloride at 130 °C to furnish the compound (3 c) of formula II
In another embodiment of the present invention the process for the preparation of compound of general formula I, the said process comprising of
Reacting compound 3c (formula II) with hydroxylamine hydrochloride in the presence of a base like sodium acetate or pyridine and solvent used is absolute ethanol/methanol to furnish the compound 4c of formula I. (Scheme 4).
In another embodiment of the present invention, the reactions to furnish the compound of formula I are carried out without any catalyst. In yet another embodiment of the invention a method for treatment of cancer in a subject comprising, administring to a subject in need thereof an effective amount of a compound of formula 1.
In a more preferred embodiment of the invention, the compound is for use in the treatment of leukemia.
In even preferred embodiment of the invention, the compound is for use in suppression of BCR-ABL activity in CML thereof.
In even more preferred embodiment of the invention, the compound is for use in suppression of c-SRC activity in imatinib-resistance in CML thereof.
In a more preferred embodiment of the invention, the compound is for use in inducing apoptosis in imatinib-resistant CML cells.
In a preferred embodiment of the invention, the compound is for use in inducing of apoptosis and differentiation in AML cells.
In another embodiment of the invention, the compound is for use in inducing megakaryocyte differentiation in K562 cells and inducing differentiation in blast cells of erythroleukemia or increasing platelet amount.
In a morepreferred embodiment of the invention, the compound is for use in exhibiting cancer-specific cytotoxicity in ER-positive or ER-negative breast cancer cells, prostate cancer cells, utemine adenocarcinoma and colon cancer cells..
In an even preferred embodiment of the invention, the compound is for use in selective cytotoxicity towards cancer stem cells such as but not limited to CD133+ colon cancer stem cells.
In another embodiment of the invention, the representative compounds of formula I and its salts thereof are used for the treatment of solid tumors and hematological malignancy, more particularly their use in treatment of leukemia, acute leukemia, lymphoma and multiple myeloma.
In another embodiment of the present invention, the pharmaceutical composition is provided comprising an effective amount of a compound of formula I optionally along with a pharmaceutically acceptable carrier or diluents. In another embodiment of the present invention, the compound is for use as anticancer agent and for treatment of hematological malignancy such as their use in treatment of leukemia, acute leukemia, lymphoma and multiple myeloma and as well as in solid tumors.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1: CentANS induces apoptotic cell death in K562 and HL-60 cells
Fig. 2: CentANS induces G0/G1 growth arrest in K562 and HL-60 cells.
Fig. 3: Centans induces dephosphorylation of BCR-ABL and SRC protooncogene.
Fig. 4: Centans induces megakaryocyte differentiation in K562 Cells
Fig. 5: Centans induces Granulocytic/monocytic differentiation in HL-60 cells.
Fig. 6: Centans induces apoptotic cell death in breast cancer cells
Fig. 7: Centans induces dephosphorylation of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (Her2).
Fig. 8: Centans causes reduction of tumor volume in vivo.
Fig. 9: Centans reduces CD133+ colon cancer stem cells.
ABBREVIATIONS
Centans: Abbreviation used for compounds based on the IUPAC name of the compound, prefixed with Cent; a Central Drug Research Institute signature.
CML: Chronic myelogenous leukemia
AML: Acute myelogenous leukemia
PBMC: Peripheral blood mononuclear cells
BCR: "Break point cluster region" gene
ABL: Abelson murine leukemia viral oncogene homolog 1
BCR-ABL: a fusion protein of BCR and ABL
APOP: Apoptosis
Stat5: Signal transducer and activator of transciption 5 Crkl: v-CRK avian sarcoma virus CT10-homo log-like
eIF4E: Eukaryotic translation initiation factor 4E
GATA-2: GATA binding protein 2
ER: Estrogen Receptor
MTT: 3-(4,5-dimethythiazol-. 2-yl)-2,5-diphenyl tetrazolium bromide
PI: Propidium Iodide
DETAILED DESCRIPTION OF THE INVENTION
Accordingly, the present invention provides the process for preparation of substituted aryl naphthyl methanone oximes of general formula (I) and their derivatives, salts, pharmaceutical composition thereof and their use in treatment of chronic myelogenous leukemia, acute myelogenous leukemia, lymphoma, multiple myeloma, breast cancer, endometrial cancer prostate cancer and colon cancer as subject in need thereof.
The present invention provides substituted aryl naphthyl methanone oxime (s) of formula (I), for use in the treatment of hematological malignancy, particularly for use in treatment of leukemia, acute leukemia, lymphoma and multiple myeloma and solid tumors such as breast cancer, endometrial cancer, prostate cancer and colon cancer.
Figure imgf000021_0001
Formula I
R'= H, halogen, alky), alkoxy, nlro
R2 = H, halogen, alkyl, alkoxy, hydroxy, nilro
R3 = H, alkyl, alkoxy, nitro, halogen
X = O, S
R4 = hydrogen, alkyl group (c,-<¾). alkylamlno group (c,-ce), cyclic or open chain amines
R*= hydrogen, alkyl group (ci ). alkylepoxy.alkythydroxyamlno group
-ce).alkylamino group cyclic or open chain amines, alkyl ester and amides derivatives
Figure imgf000021_0002
m = 1 , 2 , 3, 4
This invention also relates to a process for the preparation of Substituted Aryl naphthyl methanone cixime (s). Reacting the substituted Naphthalene- 1-carboxylic acid (1) and suitably substituted phenol or thiophenol (2) in the presence of PPA at 90 °C to yield compound 3b. (Formula II) [Atul Kumar, S. R. Pathak, Pervez Ahmad, S. Ray, P. Tewari, A. K. Srivastava Bioorganic & Medicinal Chemistry Letters 16 (2006) 2719-2723].
Figure imgf000022_0001
Formula II Formula I
(Compound 3) (compound 4,9)
R1 = H, halogen, alkyl, alkoxy, nitro
R2 = H. halogen, alky(, alkoxy, hydroxy, nitro
R3= H, alkyl, alkoxy, nitro, halogen
X = o, s
R4= hydrogen, alkyl group (ο·,-<¾), alkyiamino group (ct-ce), cyclic or open chain amines
Rs= H
Scheme-1 The compound 3 on treatment with a hydroxylamine hydrochloride in the presence of base like pyridine, sodium acetate in dry ethanol yields compound 4. (Formula I)
Compound 4 on treatment with a number of alkyl halides in the presence of base, like K2CO3, CSCO3, KOH,NaH etc. in dry DMF or acetone, yields compound 5, 6 of formula I.
Compound 4 on treatment with various dihaloalkanes in the presence of base, like K2CO3, CSCO3 etc. in dry DMF/ acetone also yields compound 5n, o (formula I), which on reaction with a number of amines in dry DMF/Methanol yields compound 7 & 8 of formula I (Scheme 2).
Compound 4b on treatment with HBr/acetic acid, HBr HiO, BBr3 or pyridine hydrochloride yields compound 4c (formula I).
Following examples are given by way of illustrations and therefore, should not be construed to limit the scope of the present invention: EXAMPLES
Synthesis of Compounds
The following examples are given by way of illustrating the present invention and should not be construed to limit the scope of the invention:
EXAMPLE 1: Synthesis of (4-(methylthio)phenyl)(naphthaIen-l-yl)methanone oxime (Compound 4a)
Figure imgf000023_0001
Into a 50 ml round bottom flask, (4-Methylsulfanyl-phenyI)-naphthalen-l-yl- methanone (1 mmole, 278mg), hydroxylamine hydrochloride (2mmole, 140mg), dry pyridine (0.5 ml) and absolute ethanol (7.0 ml) were taken to obtain a reaction mixture. The reaction mixture was refluxed at 80° C under anhydrous conditions for 8 hours. The reaction was followed by TLC (thin layer chromatography) monitoring. After completion of the reaction, ethanol was evaporated under reduced pressure. The resulting mixture was poured onto crushed ice and extracted with ethyl acetate (3x50 ml), washed with water until pH =7, dried over anhydrous Na2S04 (8-9g) and concentrated. The crude product was purified by silica gel column chromatography using ethyl acetate and distilled Hexane as an eluent (8%) to yield the pure productlt was then recrystellize from ethyl acetate and Hexane. Yield: 215 mg,
73.4%.
M.P.= 135 °C, ESI MS (m/z)= 294(M+H); IR(KBr, Cm"1): 3235.8, 2921.5, 1899.5, 1591.0, 1491.1, 1434.8, 1390.9, 1352.4, 1313.1, 1093.0, 1074.0, 969.6, 922.0, 770.1, 695.6; Ή NMR(CDC13, 300MHz): 6=7.99(t, J=8.7 Hz, 2H, ArH), 7.73(d, J=8.1 Hz, 1H, ArH), 7.64-7.33(m, 6H, ArH), 7.16(d, J=7.2 Hz, 2H, ArH), 2.46(s, 3H, SCH3); 13C NMR (CDC13, 50 MHz): 6 = 157.43, 141.26, 133.89, 132.75, 131.73, 130.80, 129.61, 128.89, 127.84(2), 127.14, 126.74, 126.54(2), 126.23, 126.09, 125.73, 15.67; Analysis calculated for CsHisNOS: C, 73.69; H, 5.15; N, 4.77, found: C, 73.71; H, 5.16; N, 4.80. EXAMPLE 2: Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methanone oxime (Compound 4b).
Figure imgf000024_0001
Into a 50 ml round bottom flask, (4-Methoxy phenyl)-naphthalen-l-yl-methanone (1 mmole, 262mg), hydroxylamine hydrochloride (2mmole, 140mg), dry pyridine (0.5 ml) and absolute ethanol (7.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 8 hours. The reaction was followed by TLC monitoring. After completion of the reaction, ethanol was evaporated under reduced pressure. The resulting mixture was poured onto crushed ice and extracted with ethyl acetate (3x50 ml), washed with water until pH =7, dried over anhydrous Na2S04 and concentrated. The crude product was purified by silica gel column chromatography using ethyl acetate and distilled Hexane as an eluent (6%) to yield the pure product. It was then recrystallized from ethyl acetate and Hexane. Yield: 209 mg, 75.45%.
M.P. = 132°C; ESI MS(m/z) = 278(M+H); IR (KBr, Cm'1): 3254.2, 3056.7, 2924.9, 1603.6, 1510.5, 1460.0, 1252.1, 1176.3, 1025.4, 970.4, 928.8, 835.0, 771.8; Ή NMR(CDC13, 300MHz): 6= 7.95(t, J=6.6 Hz, 2H, ArH), 7.76(d, J=8.1 Hz, 1H, ArH), 7.63-7.39(m, 6H, ArH), 6.83(d, J=8.9 Hz, 2H, ArH), 3.79(s, 3H, OCH3); 13C NMR (CDC13, 75MHz): 160.82, 156.91, 133.51, 132.14, 131.87, 130.47, 129.11, 128.65, 128.48, 128.39, 126.72, 126.32, 126.13, 125.87, 125.38, 125.20, 113.91, 55.32; Analysis calculated for Ci8Hi5N02: C, 77.96; H, 5.45; N, 5.05, found: C, 77.97; H, 5.43; N, 5.07.
EXAMPLE 3: Synthesis of (4-hydroxyphenyl)(naphthaIen-l-yl)rnethanone oxime (Compound 4c).
Figure imgf000024_0002
Into a 50 ml round bottom flask, (4-Hydroxy-phenyl)-naphthalen-l-yl-methanone (1 mmole, 248mg), hydroxylamine hydrochloride (2mmole, 140mg), dry pyridine (0.5 ml) and absolute ethanol (7.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 7 hours. The reaction was followed by TLC monitoring. After completion of the reaction, ethanol was evaporated under reduced pressure. The resulting mixture was poured onto crushed ice and extracted with ethyl acetate (3x50 ml), washed with water until pH =7, dried over anhydrous Na2S04 and concentrated. The crude product was purified by silica gel column chromatography using chloroform as eluent to yield the pure product. It was then recrystellized with ethyl acetate and hexane. Yield: 221 mg, 84.03%.ESI MS (m/z) = 264 (M+H); Ή NMR (200MHz, CDC13): δ= 7.91(t, J=8.0 Hz, 2H, ArH), 7.71(d, J=8.0 Hz, 1H, ArH), 7.55-7.31(m, 5H, ArH), 7.26(m, 1H, ArH), 6.52-6.47(m, 2H, ArH); l 3C NMR(CDC13+CD30D, 75MHz): 159.61 , 157.99, 134.92, 134.07, 131.88, 129.84, 129.78(2), 129.51, 129.37, 127.50, 127.27, 127.1 1, 126.94, 126.48, 1 16.41 ; Analysis calculated for d7Hl3N02: C, 77.55; H, 4.98; N, 5.32, found: C, 77.50; H, 5.06; N, 5.26.
EXAMPLE 4: Synthesis of (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2-(piperidin-l-yl)ethyl oxime oxalate (Compound 5a).
Figure imgf000025_0001
Into a 50 ml round bottom flask, 4-(methylthiophenyl)(naphthalen-l-yl)methanone oxime (1 mmole, 293 mg), 1 -(2-chloroethyl)piperidine hydrochloride (1.2 mmole, 220.8 mg), baked K2CO3 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, 2C03 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (349rag, 86.6%). The product obtained was oily, so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, lmmole/ lmmole of compound, (109.1 mg) and oily product (349 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 390 mg, 85.2%.
M.P. (Oxalate Salt of compound)= 155°C, ESI MS (m/z) = 404 ; IR (KBr, Cm-1) = 3020.4, 2970.1, 2360.8, 1758.4, 1630.1, 1522.3, 1216.4, 761.8, 670.3; Ή NMR(CDC13, 200MHz): δ= 7.94 (d, J=8.0 Hz, 2H, ArH), 7.63-7.41 (m, 5H, ArH), 7.29-7.27(m, 2H, ArH), 7.18 (d, J=8.2 Hz, 2H, ArH), 4.46(m, 2H, OCH2), 3.21(m, 4H, NCH2)2.47-2.46(m, 5H, SCH3 & NCH2), 1.51(m, 5H, CH2). Analysis calculated for C25H28N2OS: C, 74.22; H, 6.98; N, 6.92; found: C, 74.25; H, 6.95; N, 6.96.
EXAMPLE 5: Synthesis of (4-(methylthio)phenyl)(naphthaIen-l-yl)methanone 0-2-(pyrroIidin-l-yl)ethyl oxime oxalate (Compound Sb).
Figure imgf000026_0001
Into a 50 ml round bottom flask, 4-(methylthiophenyl)(naphthalen-l-yl)methanone oxime (1 mmole, 293 mg), l-(2-chloroethyl)pyrrolidine hydrochloride (1.2 mmole, 204 mg), baked K2C03 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K2CO3 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (250mg, 64.26%). The product obtained was oily, so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, lmmole/ lmmole of compound, (108.9 mg) and oily product (250 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 390 mg, 85.2%.
M.P. (Oxalate Salt of compound)= 153° C, ESI MS (m/z)= 390 (M+H); IR (KBr, Cm-1) = 3021.01, 2359.2, 1757.5, 1629.5, 1216.6, 761.0, 671.4; Ή NMR (CDC13, 200MHz): 5=7.93 (d, J=7.6 Hz, 2H, ArH), 7.62-7.41 (m, 5H, ArH), 7.29-7.27(m, 2H, ArH), 7.17 (d, J=8.4 Hz, 2H, ArH), 4.61-4.45(m, 2H, OCH2), 3.29(m, 2H, NCH2), 2.82-2.80(m, 4H, NCH2), 2.47(s, 3H, SCH3), 1.70(m, 4H, CH2). Analysis calculated for C24H26N2OS (free base): C, 73.81; H, 6.71; N, 7.17, found: C, 73.79; H, 6.68; N,
7.15.
EXAMPLE 6: Synthesis of (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2-(dimethylamino)ethyl oxime oxalate (Compound 5c).
Figure imgf000027_0001
Into a 50 ml round bottom flask, 4-(methylthiophenyl) (naphthalen-l-yl)methanone oxime (1 mmole, 293 mg), (2-Chloro-ethyl)-dimethyl-amine hydrochloride (1.2 mmole, 172.8 mg), baked K2C03 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, 2C03 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (280mg, 76.9%). The product obtained was oily, so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, lmmole/ lmmole of compound, (96.9 mg) and oily product (280 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 310 mg, 63.27%. M. P. (Oxalate Salt of compound)= 105°C; ESI MS (m/z)= 365 (M+H), IR (KBr, Cm"1): 3020.5, 2970.8, 2362.1, 1757.3, 1629.1, 1216.4, 1044.6, 760.9, 670.2; Ή NMR (CDC13, 200MHz): 5=7.93 (d, J=7.7 Hz, 2H, ArH), 7.61-7.4l(m, 5H, ArH), 7.28-7.25(m, 2H, ArH), 7.17(d, J=8.4 Hz, 2H, ArH), 4.65-4.49(ra, 2H, OCH2), 3.47(s, 6H, NCH3), 2.45(s, 3H, SCH3), 2.40(m, 2H, NCH2). Analysis calculated for C22H24N2OS (free base): C, 72.49; H, 6.64; N, 7.69; Found: C, 72.46; H, 6.63; N, 7.67.
EXAMPLE 7: Synthesis of (4-(methylthio)phenyl)(naphthaIen-l-yl)methanone 0-2-(diethylamino)ethyl oxime oxalate (Compound 5d)
Figure imgf000028_0001
Method A: Into a 50 ml round bottom flask, 4-(methylthiophenyl)(naphthalen-l- yl)methanone oxime (1 mmole, 293 mg), 2-chloro-N,N-diethylethanamine hydrochloride (1.2 mmole, 205 mg), baked K2C03 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K2C0 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (250 mg, 63.6%). The product obtained was oily so a salt of the compound was prepared. Procedure for oxalate salt formation: Oxalic acid, 1 mmole/ 1 mmole of compound, (80.15 mg) and the oily product (250 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 259 mg, 48.3%.
M.P. (Oxalate Salt of compound)- 115 °C; ESI MS (m/z)= 393 (M+H); Ή NMR(CDC13, 200MHz): δ=7.93 (d, J=8.0 Hz, 2H, ArH), 7.63-7.41(m, 5H, ArH), 7.27-7.25(m, 2H, ArH), 7.17-7.13(d, J=8.0 Hz, 2H, ArH), 4.48(m, 2H, OCH2), 3.26(m, 2H, NCH2), 2.72(m, 4H, NCH2), 2.46(s, 3H, SCH3), 0.81(m, 6H, CH3); Analysis calculated for C26H3oN205S: C, 64.71; H, 6.27; N, 5.80 found: C, 64.76; H, 6.26; N, 5.85.
Method B: Into a 50 ml round bottom flask, 4-(methylthiophenyl)(naphthalen-l- yl)methanone oxime (1 mmole, 293 mg), 2-chloro-N,N-diethylethanamine hydrochloride ( 1.2 mmole, 205 mg), Cs2C03 (5 mmole) and dry DMF (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 5 hours. The reaction was followed by TLC monitoring. After completion of the reaction, filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (62.6%).
EXAMPLE 8: Synthesis of (4-(methylthio)phenyl)(naphthaIen-l-yl)methanone 0-2-(diisopropylamino)ethyI oxime (Compound 5e).
Figure imgf000029_0001
Into a 50 ml round bottom flask, 4-(methylthiophenyl) (naphthalen-l-yl)methanone oxime (1 mmole, 293 mg), (2-Chloro-ethyl)-diisopropyl-amine hydrochloride (1.2 mmole, 240 mg), baked K2C03 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K2C0 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (325mg, 77.38%). Oily Compound; ESI MS(m/z)= 421(M+H); Ή NMR(CDC13, 200MHz): 7.92(d, J=7.6 Hz, 2H, ArH),7.57-7.39(m, 5H, ArH), 7.32-7.26(m, 2H, ArH), 7.15 (d, J=8.5 Hz, 2H, ArH), 4.09 (t, J=7.2 Hz, 2H, OCH2), 2.94-2.88(m, 2H, NCH), 2.68(m, 2H, NCH2), 2.45(s, 3H, SCH3), 0.93-0.89(d, J=6.5 Hz, 12H, CH3). Analysis calculated for C26H32N2OS: C, 74.24; H, 7.67; N, 6.66, found: C, 74.20; H, 7.65; N, 6.65. Example 9: Synthesis of (4-(methyIthio)phenyl)(naphthalen-l-yI)niethanoae O- 2-morpholinoethyl oxime (Compound 5f).
Figure imgf000030_0001
Into a 50 ml round bottom flask, 4-( methyl thiophenyl) (naphthalen-l-yl)methanone oxime (1 mmole, 293 mg), 4-(2-Chloro-ethyl)-morpholine hydrochloride (1.2 mmole, 223.2 mg), baked 2CO3 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K2CC>3 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (298mg, 73.22%). Oily compound, ESI MS(m/z) = 407 (M+H); IR(Neat, Cm-1): 4300.2, 3020.6, 1757.4, 1593.6, 1216.5, 1042.5, 762.0, 671.3; Ή (300MHz, CDC13): 5=7.93(d, J=8.3 Hz, 2H, ArH), 7.68 (d, J=8.2 Hz, 1H, ArH), 7.58-7.40(m, 5H, ArH), 7.32- 7.28(m, 1H, ArH), 7.18(d, J=8.4 Hz, 2H, ArH), 4.33(t, J=5.6 Hz, 2H, OCH2), 3.77- 3.51(m, 4H, OCH2), 2.63(t, J=5.6 Hz, 2H, NCH2), 2.47(s, 3H, SCH3), 2.27(t, J=4.3 Hz, 4H, NCH2); Analysis calculated for C24H26N202S: C, 70.90; H, 6.45; N, 6.89, found: C, 70.89; H, 6.40; N, 6.86.
Example 10: Synthesis of (4-(methylthio)phenyl)(naphthaIen-l-yI)methanone 0-l-(dimethyIamino)propan-2-yl oxime oxalate (Compound 5g).
Figure imgf000030_0002
Method A: Into a 50 ml round bottom flask, 4-(methylthio)phenyl (naphthalen-1- yl)methanone oxime (1 mmole, 293 mg), (2-Chloro-propyl)-dimethyl-amine hydrochloride ( 1.2 mmole, 189.6 mg), baked K2C03 (5 mmole, 690 mg) and dry DMF (10.0 ml) were taken. The reaction mixture was refiuxed under anhydrous conditions for 5 hours. The reaction was followed by TLC monitoring. After completion of the reaction, the mixture was quenched into water (100ml), extracted with ethyl acetate (3X75ml) and dried over anhydrous Na2SC>4. The filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (67.13%). The product obtained was oily so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, Immole/ lmmole of compound, (83.3 mg) and oily product (250 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 260 mg, 64.35%.
M.P. (Oxalate Salt of compound) = 101°C, ESI MS (m/z) = 379 (M+H); IR (KBr, Cm"')= 3020.7, 2361.4, 1761.8, 1631.9, 1525.6, 1426.5, 1216.1, 761.0, 670.3; Ή NMR(300MHz, CDC13): δ= 7.9240(d, J=7.8 Hz, 2H, ArH) 7.6788(d, J=8.2 Hz, 1H, ArH), 7.5763-7.3997(m, 5H, ArH), 7.3223-7.2806(m, 1H, ArH), 7.1766(d, J=8.4 Hz, 2Ή, ArH), 4.0737-4.0187(m, 1H, OCH), 3.0861-2.8784(m, 2H, NCH2), 2.4656(s, 3H, SCH3), 2.1236(s, 6H, NCH3), 0.9154(d, J=6.0 Hz, 3H, CH-CH3); Analysis calculated for C23H26N2OS(free base): C, 72.98; H, 6.92; N, 7.40, found: C, 72.93; H, 6.88; N, 7.37.
Method B: Into a 50 ml round bottom flask, 4-(methylthio)phenyl (naphthalen-1- yl)methanone oxime (I mmole, 293 mg), (2-Chloro-propyl)-dimethyl-amine hydrochloride (1.2 mmole, 189.6 mg), baked 2CO3 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refiuxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K2C03 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (250mg, 66.13%). EXAMPLE 11: Synthesis of (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2-(azepan-l-yl)ethyl oxime oxalate (Compound 5h).
Figure imgf000032_0001
Into a 50 ml round bottom flask, 4-(methylthio)phenyl (naphthalen-l-yl)methanone oxime (1 mmole, 293 mg), l-(2-Chloro-ethyl)-azepane hydrochloride (1.2 mmole, 237.6 mg), baked K2CO3 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, 2CO3 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (350mg, 83.7%). The product obtained was oily so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, 1 mmole/ 1 mmole of compound, (105.5 mg) and oily product (350 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 427 mg, 78.49%.
M.P. (Oxalate Salt of compound) =145° C; ESI MS(m/z)= 419 (M+H); ); IR(KBr, Cm-1): 3444.7, 2931.2, 2604.7, 1921.2, 1741.9, 1430.3, 1246.1, 1095.6, 1066.0, 961.0, 777.3; Ή NMR(300MHz, CDCI3): δ= 7.93(d, J=8.2 Hz, 2H, ArH), 7.68(d, J=8.2 Hz, 1H, ArH), 7.58-7.39(m, 5H, ArH), 7.33-7.28(m, 1H, ArH), 7.18(d, J=8.6 Hz, 2H, ArH), 4.28(t, J=6.1 Hz, 2H, OCH2), 2.78(t, J=.5 Hz, 2H, NCH2), 2.51(m,. 4H, NCH2), 2.47(s, 3H, SCH3), 1.49(m, 8H, CH2); Analysis Calculated for C26H30N2OS (free base): C, 74.60; H, 7.22; N, 6.69, found: C, 74.62; H, 7.20; N, 6.68.
EXAMPLE 12: Synthesis of (4-(methylthio)phenyl)(naphthalen-l- yl)methanone 0-2-(diethyIamino)ethyl oxime citrate (Compound 5i)
Figure imgf000033_0001
Procedure for citrate salt formation: citric acid, lmmole/ Immole of compound, (122.45 mg) and (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2- (diethylamino) ethyl oxime (250 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and-, shaken thoroughly and kept in refrigerator for overnight after adding dry diethyl ether. The salt was filtered, washed with dry diethyl ether and collected. Yield: 49%. Analysis calculated for C30H36N2O8SC, 61.63; H, 6.21; N, 4.79; found: C, 61.62; H, 6.17; N, 4.75.
EXAMPLE 13: Synthesis of (4-(methylthio)phenyI)(naphthalen-l-yl)methanone 0-2-(diethylamino)ethyl oxime fumarate (Compound 5j)
Figure imgf000033_0002
Procedure for fumarate salt formation: fumaric acid, lmmole/ lmmole of compound, (73.98 mg) and (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2- (diethylamino)ethyl oxime (250 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly and kept in refrigerator for overnight after adding dry diethyl ether. The salt was filtered, washed with dry diethyl ether and collected. Yield: 48.3%. Analysis calculated for C28H32N205S, C, 66.12; H, 6.34; N, 5.51; found: C, 66.13; H, 6.37; N, 5.55.
EXAMPLE 14: Synthesis of (4-(methylthio)phenyl)(aaphthalen-l-yl)methanone 0-2-(diethylamino)ethyl oxime tartrate (Compound 5k)
Figure imgf000034_0001
Procedure for tartrate salt formation: tartric acid, lmmole/ lmmole of compound, (95.66 mg) and (4-, (methylthio)phenyl)(naphthalen- 1 -yl)methanone 0-2-(diethylamino)ethyl oxime (250 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly and kept in refrigerator for overnight after adding dry diethyl ether. The salt was filtered, washed with dry diethyl ether and collected. Yield: 51%. Analysis calculated for C28H34N207S, C, 61.97; H, 6.32; N, 5.16; found: C, 61.93; H, 6.30; N, 5.11.
EXAMPLE 15: Synthesis of (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2-(diethylamino)ethyl oxime (Compound 51)
Figure imgf000034_0002
Into a 50 ml round bottom flask, 4-(methylthiophenyl)(naphthalen-l-yl)methanone oxime (1 mmole, 293 mg), 2-chloro-N,N-diethylethanamine hydrochloride (1.2 mmole, 205 mg), baked K2C03 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, 2CO3 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (250 mg, 63.6%).
The product obtained was oily so a salt of the compound was prepared. ESI MS (m/z)= 393 (M+H); IR (KBr, Cm-1): 3445.9, 2939.4, 2362.7, 1742.4, 1645.1, 1400.5, 1235.1, 964.2, 718.3; 'H NMR(CDC13, 200MHz): 8=7.93(d, J=S.0 Hz, 2H, ArH), 7.63-7.41(m, 5H, ArH), 7.27-7.25(m, 2H, ArH), 7.17-7.13(d, J=8.0 Hz, 2H, ArH), 4.48(m, 2H, OCH2), 3.26(m, 2H, NCH2), 2.72(m, 4H, NCH2), 2.46(s, 3H, SCH3), 0.81(m, 6H, CH3); Analysis calculated for C24H28N2OS: C, 73.43; H, 7.19; N, 7.14, found: C, 73.41; H, 7.15; N, 7.10.
EXAMPLE 16: Synthesis of (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-3-(dimethylamino)propyl oxime oxalate (Compound 5m)
Figure imgf000035_0001
Into a 50 ml round bottom flask, 4-(methylthiophenyl)(naphthalen-l-yl)methanone oxime (1 mmole, 293 mg), 3-chloro-N,N-dimethylpropan-l-amine hydrochloride (1.2 mmole, 190 mg), baked K2C03 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K2C03 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (240 mg, 63.5%). The product obtained was oily so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, lmmole/ lmmole of compound, (80 mg) and oily product (240 mg) were dissolved in dry methanol separately into two round bottom flasks.The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: '251 mg, 49.8%.
M.P. (Oxalate Salt of compound^ 110°C; ESI MS (m/z)= 379 (M+H); IR (KBr, Cm-1): 3448.1, 2938.1, 2682.5, 1621.9, 1471.4, 1240.3, 1048.1, 719.1; Ή NMR(CD3OD, 200MHz): δ= 7.97 (d, J=8.2 Hz, 2H, ArH), 7.60-7.44(m, 5H, ArH), 7.39-7.26(m, 2H, ArH), 7.16(d, J=8.0 Hz, 2H, ArH), 4.21-4.16(t, J=5.6 Hz 2H, OCH2), 2,90-2.85(m, 2H, NCH2), 2.63(s, 6H, NCH3), 2.43(s, 3H, SCH3), 2.02- 1.96(m, 2H, CH2); Analysis calculated for C23H26N2OS(Free base): C, 72.98; H, 6.92; N, 7.40, found: C, 72.95; H, 6.89; N, 7.38. EXAMPLE 17: Synthesis of (4-(methylthio)phenyl)(naphthalen-l-yl)raethanone O-3-chIoropropyI oxime (Compound 5n).
Figure imgf000036_0001
Into a 50 ml round bottom flask, 4-(methylthiophenyl) (naphthalen-l-yl)methanone oxime (2 mmole, 586 mg), l-bromo-3-chloropropane (4 mmole, 0.39 ml), baked K2C03 (10 mmole, 1380 mg) and dry acetone (15.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 8 hours. The reaction was followed by TLC monitoring. After completion of the reaction, 2C03 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by silica gel column chromatography using distilled Hexane to yield the pure product (510 mg, 69.11 %).
Oily compound, ESI MS(m/z) = 370 (M+H); IR(Neat, Cm-'): 3464.5, 3055,8, 1594.0, 1493.4, 1437.8, 1314.6, 1217.4, 1095.5, 1042.5, 964.0, 758.3; Ή(200 Ηζ, CDC13): δ= 7.92(d, J=6 Hz, 2H, ArH), 7.66-7.41(m, 6H, ArH), 7.32-7.26(m, 1H, ArH), 7.17(d, J=8 Hz, 2H, ArH), 4.28(t, J=4.9 Hz, 2H, OCH2), 3.42(t, J=6.7 Hz, 2H, CH2C1), 2.46(s, 3H, SCH3), 2.10-2.04(m, 2H,CH2); Analysis calculated for C2|H20C1NOS: C, 68.19; H, 5.45; N, 3.79, found: C, 68.21; H, 5.44; N, 3.80.
Example 18: Synthesis of (4-(methylthio)phenyl)(naphthalen-l-yl)methanone O-4-chlorobutyl oxime (Compound 5o).
Figure imgf000036_0002
Into a 50 ml round bottom flask 4-(methylthiophenyl) (naphthalen-l-yl)methanone oxime (2 mmole, 586 mg), 1 -bromo-4-chlorobutane (4 mmole, 0.46 ml), baked K2C03 ( 10 mmole, 1380 mg) and dry acetone (15.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 8 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K2CO3 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by silica gel column chromatography using distilled Hexane to yield the pure product (547 mg, 71.22%).
Oily compound, ESI MS (m/z) = 385 (M+H); Ή (200MHz, CDCb): 5= 7.92(d, J=7.6 Hz, 2H, ArH), 7.55-7.39(m, 6H, ArH), 7.32-7.20(m, 1H, ArH), 7.17(d, J=8.5 Hz, 2H, ArH), 4.19(t, J=5.7 Hz, 2H, OCH2), 3.42(t, J=6.5 Hz, 2H, CH2C1), 2.46(s, 3H, SCH3), 1.79-1.61(m, 4H, CH2); Analysis calculated for C22H22C1N0S: C, 68.82; H, 5.78; N, 3.65; found: C, 68.80; H, 5.76; N, 3.64.
EXAMPLE 19: Synthesis of Ethyl 2-((4-(methylthio)phenyl) (naphthalen-l-yl) meth leneaminooxy) acetate (Compound 5p)
Figure imgf000037_0001
Into a 50 ml round bottom flask, 4-(methylthiophenyl)(naphthalen-l-yl)methanone oxime (1 mmole, 293 mg), ethyl -2-bromoacetate (1.2 mmole), baked K2C03 (5 mmole) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, 2CO3 was filtered off and washed with acetone (2 10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (65.0%).
ESI MS (m/z)= 393 (M+H); Ή NMR(CDC13, 300MHz): 5=7.93(d, J=6.0 Hz, 2H, ArH), 7.64-7.43(m, 7H, ArH), 7.16(d, J=6.0 Hz, 2H, ArH), 4.62(s, 1H, OCH2), 4.16(q, J=12.0 Hz, 2H, OCH2), 2.45(s, 3H, SCH3), 1.34 (t, J=12.0 Hz, 3H, CH3); Analysis calculated for C22H2iN03S: C, 69.63; H, 5.58; N, 3.69; found: C, 69.60; H, 5.53; N, 3.66. EXAMPLE 20: Synthesis of N,N-diethyl-2-((4-(methylthio)phenyl) (naphthaIen-l-yl)methyleneaminooxy)acetamide (Compound 5q)
Figure imgf000038_0001
Into a microwave vial (2-5 cm), ethyl 2-((4-(methylthio)phenyl)(naphfhalen-l- yl)methyleneaminooxy)acetate (379mg, lmmole) and potassium tertiary butoxide (1 mmole) and diethylamine (1 mmole) was taken. The reaction mixture was then irradiated to microwave for 3 min. On completion of the reaction, the mixture was diluted with 15 ml of dichloromethane and extracted. It was then washed with brine, then with water and dried over anhydrous Na2S04. The crude product was purified by silica gel column chromatography using 1% MeOH/CHCl3 as eluent to yield the pure product. Yield: 54.3%. lH NMR(CDCl3, 300MHz): 5=7.92(d, J=8.0 Hz, 2H, ArH), 7.70(d, J=9.0 Hz, 1H, ArH), 7.62-7.46(m, 6H, ArH), 7.36-7.31(m, 1H, ArH), 7.20(d, J=9.0 Hz, 2H, ArH), 4.71(s, 2H, OCH2), 4.02(q, J=6.0 Hz, 4H, NCH2), 2.50(s, 3H, SCH3), 1.86(t, 6H, CH3); Analysis calculated for C24H26N202S: C, 70.90; H, 6.45; N, 6.89; found: C, 70.95; H, 6.43; N, 6.84.
EXAMPLE 21: Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methanone O- 2-(piperidin-l-yl)ethyl oxime oxalate (Compound 6a).
Figure imgf000038_0002
Into a 50 ml round bottom flask, (4-(methoxy phenyl)(naphthalen-l-yl)methanone oxime (1 mmole, 277 mg), l-(2-chloroethyl)piperidine hydrochloride (1.2 mmole, 220.8 mg), baked K2C03 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K2C03 was filtered off and washed with acetone (2x10 ml). The filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (312mg, 80.41 %). The product obtained was oily so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, lmmole/ lmmole of compound, (101.3 mg) and oily product (312 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 364 mg, 70.82%.
M. P. (Oxalate Salt of compound) = 171°C; ESI MS (m z): 389 (M+H), IR (KBr, Cm-1): 3409.7, 3020.1, 2959.6, 2361.4, 1771.7, 1609.9, 1513.2, 1216.1, 1030.0, 761.0, 670.1. Ή NMR(CDC13, 300MHz): 5=7.92(d, J=8.0 Hz, 2H, ArH), 7.71(d, J=8.2 Hz, 1H, ArH), 7.58-7.42(m, 5H, ArH), 7.33-7.28(m, 1H, ArH), 6.84(d, J=8.8 Hz, 2H, ArH), 4.30(t, J=6.0 Hz, 2H, OCH2), 3.80(s, 3H, OCH3), 2.62(t, J=5.4 Hz, 2H, NCH2), 2.25-2.23(m, 4H, NCH2), 1.48-1.43(m, 4H, CH2), 1.34-1.28(m, 2H, CH2); Analysis calculated for C25H28N202(free base): C, 77.29; H, 7.26; N, 7.21, found: C, 77.31; H, 7.30; N, 7.20.
EXAMPLE 22: Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methanone O- 2-(pyrrolidin-l-yl)ethyl oxime oxalate (Compound 6b).
Figure imgf000039_0001
Into a 50 ml round bottom flask, (4-(methoxy phenyl)(naphthalen-l-yl)methanone oxime (1 mmole, 277 mg), l-(2-chloroethyl)pyrrolidine hydrochloride (1.2 mmole, 204 mg), baked K2C0 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K2C0 was filtered off and washed with acetone (2x10 ml). The filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (262mg, 69.87%). The product obtained was oily so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, lmmole/ lmmole of compound, (88.02 mg) and oily product (262 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 325 mg, 64.87%.
M. P. (Oxalate Salt of compound)= 158°C; ESI MS(m/z) = 375 (M+H); IR (KBr, Cm 1): 3450.2, 3020.0, 1758.1, 1629.6, 1216.0, 1045.5, 761.6, 669.7; Ή NMR(CDC13, 300MHz): 5=7.93(d, J=8.0 Hz, 2H, ArH), 7.73(d, J=9.8 Hz, 1H, ArH), 7.58-7.42(m, 5H, ArH), 6.84(d, J=8.7 Hz, 2H, ArH), 4.32(t, J=6.1 Hz, 2H, OC¾), 3.75(8, 3H, OCH3), 2.75-2.68(m, 2H, NCH2), 2.47-2.44 (m, 4H, NCH2), 1.66-1.57 (m, 4H, CH2); Analysis calculated for C24H26N202 (free base): C, 76.98; H, 7.00; N, 7.48, found: C, 76.95; H, 7.03; N, 7.45.
EXAMPLE 23: Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methanone O- 2-(dimethylamino)ethyl oxime oxalate (Compound 6c).
Figure imgf000040_0001
Into a 50 ml round bottom flask, 4-(methylthio)phenyl (naphthalen-l-yl)methanone oxime (1 mmole, 277 mg), (2-Chloro-ethyl)-dimethyl-amine hydrochloride (1.2 mmole, 172.8 mg), baked 2C03 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, 2C03 was filtered off and washed with acetone (2x10 ml). The filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (281mg, 80.8%). The product obtained was oily so a salt of the compound was prepared. Procedure for oxalate salt formation: Oxalic acid, 1 mmole/ 1 mmole of compound, (101.8mg) and oily product (281 mg) were dissolved in dry methanol separately into two round bottom flasks.The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 329 mg, 69.4%.
M. P. (Oxalate Salt of compound)= 141°C; ESI MS (m/z)= 349 (M+H), IR (KBr, Cm-'): 3443.3, 3019.8, 2962.4, 2361.6, 1756.8, 1627.5, 1510.3, 1466.8, 1216.5, 1032.0, 761.1, 670.0; Ή NMR(CDC13, 200MHz): 6=7.92(m, 2H, ArH), 7.61- 7.37(m, 6H, ArH), 7.31-7.26(m, 1H, ArH), 6.84(d, J=6.8 Hz, 2H, ArH), 4.49(t, J=4.6 Hz, 2H, OCH2), 3.78(s, 3H, OCH3), 3.29-3.27(m, 2H, NCH2), 2.46(s, 6H, NCH3). Analysis calculated for C22H2 N202 (free base): C, 75.83; H, 6.94; N, 8.04, Found: C, 75.80; H, 6.90; N, 8.00.
EXAMPLE 24: Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methanone O- 2-(diethylamino)ethyl oxime oxalate (Compound 6d).
Figure imgf000041_0001
Into a 50 ml round bottom flask, (4-(methoxy phenyl)(naphthalen-l-yl)methanone oxime (1 mmole, 277 mg), 2-chloro-N,N-diethylethanamine hydrochloride (1.2 mmole, 205 mg), baked 2CO3 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K2CO3 was filtered off and washed with acetone (2x10 ml). The filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (289 mg, 76.86%). The product obtained was oily so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, lmmole/ lmmole of compound, (96.85 mg) and oily product (289 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 295 mg, 58.78%.
M.P.(Oxalate Salt of compound)^ 137°C; ESI MS(m/z)= 377 (M+H), IR(KBr,Cm" '): 3445.4, 2940.8, 2645.9, 1900.0, 1607.6, 1510.1 , 1313.4, 1249.4, 1 177.5, 1030.3, 963.3, 717.1; 1H NMR(CDC13, 200MHz): 5= 7.91(d, J=8.1 Hz, 2H, ArH),7.69(d, J=8.2 Hz, 1H, ArH), 7.57-7.39(m, 5H, ArH), 7.32-7.26(m, 1H, ArH), 6.83(d, J=7.1 Hz, 2H, ArH), 4.25(t, J=6.3 Hz, 2H, OCH2), 3.78(s, 3H, OCH3), 2.74(t, J=5.9 Hz, 2H, NCH2), 2.45-2.34(q, J=7.2 Hz, 4H, CH2), 0.88(t, J=7.2 Hz, 6H, CH3); Analysis calculated for C24H28N2O2: C, 76.56; H, 7.50; N, 7.44, found: C, 76.53; H, 7.52; N,
7.42.
EXAMPLE 25: Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methanone O- 2-(diisopropylamino)ethyl oxime oxalate (Compound 6e).
Figure imgf000042_0001
Into a 50 ml round bottom flask, 4-(methoxy phenyl (naphthalen-l-yl)methanone oxime (1 mmole, 277 mg), (2-Chloro-ethyl)-diisopropyl-amine hydrochloride (1.2 mmole, 240 mg), baked K2COj (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours.
The reaction was followed by TLC monitoring. After completion of the reaction,
K2CO3 was filtered off and washed with acetone (2x10 ml). The filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (318mg, 78.71%).
The product obtained was oily so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, 1 mmole/ 1 mmole of compound, (99.18 mg) and oily product (318 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 331 mg, 62.45%. M.P. (Oxalate Salt of compound^ 130°C; ESI MS(m/z)= 405 (M+H), IR (KBr, Crn '): 3445.3, 2977.4, 2691.6, 1748.4, 1638.8, 1508.0, 1394.7, 1252.6, 1 178.0, 966.1, 777.6; Ή NMR(CDC13, 200MHz): 8=7.92(d, J=8.1 Hz, 2H, ArH), 7.69(d, J=8.0 Hz, IH, ArH), 7.58-7.40(m, 5H, ArH), 7.33-7.29(m, IH, ArH), 6.83(d, J=6.9 Hz, 2H, ArH) 4.09(t, J=7.3 Hz, 2H, OCH2), 3.79(s, 3H, OCH3), 2.98-2.85(m, 2H, NCH), 2.69-2.60(m, 2H, NCHj), 0.94(d, J=6.5 Hz, 12H, CHCH3); Analysis calculated for C26H32N202: C, 77.19; H, 7.97; N, 6.92, found: C, 77.24; H, 7.99; N, 6.90.
EXAMPLE 26: Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methanone O- l-(dimethylamino)propan-2-yl oxime oxalate (Compound 6f).
Figure imgf000043_0001
Into a 50 ml round bottom flask, 4-(methoxy phenyl (naphthalen-l-yl)methanone oxime (1 mmole, 277 mg), (2-Chloro-propyl)-dimethyl-amine hydrochloride (1.2 mmole, 189.6 mg), baked 2CO3 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K2C03 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (270mg, 74.59%). The product obtained was oily so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, 1 mmole/ 1 mmole of compound, (93.98 mg) and oily product (270 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 250 mg, 51.23%.
M.P. (Oxalate Salt of compound)= 105°C; ESI MS(nVz)= 363 (M+H), IR (KBr, Cm' '): 3746.4, 2931.5, 1754.4, 1694.1, 1629.4, 1559.5, 151 1.4, 1462.6, 1252.0, 1176.7, 962.8, 739.5; Ή NMR (200MHz, CDC13): δ= 7.91(d, J=8.8 Hz, 2H, ArH), 7.69(d, J=8.1 Hz, IH, ArH), 7.54-7.39(m, 5H, ArH), 7.32-7.26(m, 2H, ArH & CHC13), 6.83(m, 2H, ArH), 4.00-3.97(m, 1H, OCH), 3.80(s, 3H, OCH3), 2.09(s, 6H, NCH3), 0.85(d, J=6.6 Hz, 3H, CH-CH3); Analysis calculated for C23H.6N202: C, 76.21; H, 7.23; N, 7.73, found: C, 76.21; H, 7.23; N, 7.73.
EXAMPLE 27: Synthesis of (4-methoxyphenyI)(naphthalen-l-yl)methanone O- 2-(azepan-l-yl)ethyl oxime oxalate (Compound 6g).
Figure imgf000044_0001
Into a 50 ml round bottom flask, 4-(methoxy phenyl (naphthalen-l-yl)methanone oxime (1 mmole, 277 mg), l-(2-Chloro-ethyl)-azepane hydrochloride (1.2 mmole, 237.6 mg), baked K2C03 (5 mmole, 690 mg) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K2C03 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (312mg, 77.61%). The product obtained was oily so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, 1 mmole/ 1 mmole of compound, (97.79 mg) and oily product (312 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 331 mg, 62.69%.
MP. (Oxalate Salt of compound)= 122 °C; ESI MS(m/z)= 403 (M+H), I (KBr, Cm-1): 3446.5, 2933.9, 2599.9, 1721.6, 1607.9, 1510.2, 1459.5, 1251.3, 1 177.9, 1026.7, 960.1, 719.2; Ή NMR (300MHz, CDC13): δ= 7.92(d, J=8.0 Hz, 2H, ArH), 7.69(d, J=8.2 Hz, 1H, ArH), 7.58-7.39(m, 5H, ArH), 7.33-7.28(m, 1H, ArH), 6.84(d, J=8.5 Hz, 2H, ArH), 4.27(t, J=6.1 Hz, 2H, OCH2), 3.80(s, 3H, OCH3), 2.78-2.67(m, 2H NCH2), 2.5 l(m, 4H NCH2), 1.49(m, 8H, CH2); Analysis calculated for C26H30N2O2: C, 77.58; H, 7.51; N, 6.96; found: C, 77.55; H, 7.53; N, 6.95. EXAMPLE 28: Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methaaone O- 2-morpholinoethyl oxime (Compound 6b)
Figure imgf000045_0001
Into a 50 ml round bottom flask, 4-(methoxy phenyl (naphthalen- l-yl)methanone oxime (1 mmole), l-(2-Chloro-ethyl)-morpholine hydrochloride (1.2 mmole), baked K2CO3 (5 mmole) and dry acetone (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 4 hours. The reaction was followed by TLC monitoring. After completion of the reaction, K2CO3 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (78.5%).
ESI MS(m/z)= 391(M+H), NMR (300MHz, CDCI3): δ= 7.94 (d, J= 8.22Hz, 2H, ArH), 7.66-7.43 (m, 6H, ArH), 7.3 l(m, 1H, ArH), 6.86(d, J= 8.9Hz, 2H, ArH), 4.47(br, s, 2H, OCH3), 3.8 l(s, 3H, OCH3), 3.60-3.53(m, 4H, OCH2), 3.25-3.24(m, 2H, OCH2), 2.71(broad, 6H NCH2); Analysis calculated for: C24H26N203: C, 73.85; H, 6.73; N, 7.20; found: C, 73.82; H, 6.71 ; N, 7.17.
EXAMPLE 29: Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methanone O- 3-(dimethylamino)propyl oxime oxalate (Compound 6i).
Figure imgf000045_0002
Into a 50 ml round bottom flask (4-(methoxy phenyl)(naphthalen-l-yl)methanone oxime (1 mmole, 277 mg), 3-chloro-N,N-dimethylpropan- 1 -amine hydrochloride ( 1.2 mmole, 190 mg), baked 2CO3 (5 mmole, 690 mg) and dry acetone ( 10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, 2CO3 was filtered off and washed with acetone (2 10 ml). Filtrate was concentrated and the crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (253 mg, 69.89%). The product obtained was oily so the salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, lmmole/ lmmole of compound, (88.06 mg) and oily product (253 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 250 mg, 65.96%.
M.P. (Oxalate Salt of compound)= 155°C; ESI MS(m/z)= 363 (M+H), IR (KBr, Cm" '): 3446.3, 3045.6, 2957.4, 2680.0, 2470.8, 1741.9, 1602.8, 1510.0, 1251.9, 1 177.4, 1043.6, 719.1; Ή NMR (200MHz, CDC13): δ= 7.92(d, J=7.7 Hz, 2H, ArH), 7.69(d, J=8.0 Hz, IH, ArH), 7.63-7.44(m, 5H, ArH), 7.32-7.28(m, 2H, ArH), 6.83(d, J=8.4 Hz, 2H, ArH), 4.17(t, J=6.0 Hz, 2H, OCH2), 3.80(s, 3H, OCH3), 2.65(m, 2H, NCH2), 2.12(s, 2H, NCH3), 1.78(m, 2H, CH2). Analysis calculated for C23H26N202: C, 76.21; H, 7.23; N, 7.73; Found: C, 76.20; H, 7.25; N, 7.70.
Example 30: Synthesis of (4-methoxyphenyl)(naphthaIen-l-yl)methanone 0-3- chloropropyl oxime (Compound 6j).
Figure imgf000046_0001
Into a 50 ml round bottom flask, (4-Methoxy-phenyl)-naphthalen- 1 -yl-methanone oxime (2 mmole, 526.58 mg), l-bromo-3-chloropropane (4 mmole, 0.39 ml), baked K2C03 (10 mmole, 1380 mg) and dry acetone (15.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 8 hours. The reaction was followed by TLC monitoring. After completion of the reaction, 2C03 was filtered off and washed with acetone (2x10 ml). Filtrate was concentrated and the crude product was purified by silica gel column chromatography using 30% chloroform/ Hexane to yield the pure product (614 mg, 86.7%).
Oily compound, ESI MS(m z) = 354 (M+H); Ή NMR (200MHz, CDC13): δ= 7.93(d, J=8.0 Hz, 2H, ArH), 7.70(m, 1H, ArH), 7.64-7.45(m, 5H, ArH), 7.33- 7.29(m, 2H, ArH), 6.84(d, J=4.0 Hz, 2H, ArH), 4.29(t, J=5.7 Hz, 2H, OCH2), 3.42- 3.35(m, 2H, CH2C1), 3.79(s, 3H, OCH3), 2.14-2.01(m, 2H,CH2); Analysis calculated for C2iH20ClNO2: C, 71.28; H, 5.70; N, 3.96; found: C, 71.32; H, 5.75; N, 3.90.
Example 31: Synthesis of (4-methoxyphenyl)(naphthalen-l-yl)methanone 0-3- ( iperidin-l-yl)propyl oxime (Compound 6k).
Figure imgf000047_0001
Into a 50 ml round bottom flask, (4-Methoxy-phenyl)-naphthalen-l-yl-methanone 0-(3-chloro-propyl)-oxime (1 mmole, 353 mg), Piperidine (5 mmole, 0.49ml) and dry methanol (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, methanol was evaporated under reduced pressure. The resulting mixture was poured onto water and extracted with ethyl acetate (3x50 ml), washed with water, dried over anhydrous Na2S04 and concentrated. The crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (289mg, 69.1 %).
Oily Compound; ESI MS (m/z)= 403 (M+H); Ή NMR (200MHz, CDC13): δ= 7.93(d, J=8 Hz, 2H, ArH), 7.70(d, J=4 Hz, 1H, ArH), 7.64-7.45(m, 5H, ArH), 7.33- 7.29(m, 1H, ArH), 6.84(d, J= Hz, 2H, ArH), 4.13-4.15(m, 2H, OCH2), 3.8(s, 3H, OCH3), 3.75(m, 2H, NCH2), 3.34(m, 2H, NCH2), 2.70-2.58(m, 2H, NCH2), 2.10- 1.71(m, 8H, CH2). Analysis calculated for C2iH20ClNO2: C, 77.58; H, 7.51; N, 6.96; found: C, 77.55; H, 7.50; N, 6.89. EXAMPLE 32: Synthesis of (4-(methyIthio)phenyl)(naphthalen-l-yl)methanone 0-3-(piperidin-l-yl)propyl oxime oxalate (Compound 7a).
Figure imgf000048_0001
Into a 50 ml round bottom flask, 4-(methylthiophenyl)(naphthalen-l-yl)methanone O-3-chloropropyl oxime (1 mmole, 369 mg), piperidine (5 mmole, 0.49 ml) and dry methanol (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, methanol was evaporated under reduced pressure. The resulting mixture was poured onto water and extracted with ethyl acetate (3x50 ml), washed with water, dried over anhydrous Na2S04 and concentrated. The crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (335mg, 75.59%).The product obtained was oily so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, 1 mmole/ 1 mmole of compound, (100.7 mg) and oily product (335 mg) were dissolved in dry methanol separately into two round bottom flasks. The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 395 mg, 90.65%.
M.P. (Oxalate Salt of compound)^ 137°C; ESI MS (m/z)= 419 (M+H); IR ( Br, Cm'1): 3854, 3740, 3443, 2925, 2358, 1753, 1633, 1553, 1220, 760; Ή NMR (300MHz, CDC13): 8=7.93(d, J=8.2 Hz, 2H, ArH), 7.64-7.38(m, 6H, ArH), 7.30(m, 1H, ArH), 7.16(d, J=8.0 Hz, 2H, ArH), 4.13(m, 2H, OCH2), 3.75(m, 2H, NCH2), 3.34(m, 2H, NCH2), 2.70-2.58(m, 2H, NCH2), 2.45(s, 3H, SCH3), 2.10-1.71(m, 8H, CH2). Analysis calculated for C26H3oN2OS: C, 74.60; H, 7.22; N, 6.69; found: C, 74.58; H, 7.20; N, 6.67. EXAMPLE 33: Synthesis of (4-(methylthio)phenyl)(aaphthaIea-l-yl)methano O-3-morpholinopropyl oxime (Compound 7b).
Figure imgf000049_0001
Into a 50 ml round bottom flask, 4-(methylthio)phenyl)(naphthalen-l-yl)methanone O-3-chloropropyl oxime (1 mmole, 369 mg), Morpholine (5 mmole, 0.44ml) and dry methanol (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, methanol was evaporated under reduced pressure. The resulting mixture was poured onto water and extracted with ethyl acetate (3x50 ml), washed with water, dried over anhydrous Na2S04 and concentrated. The crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (265mg, 60%).
M.P.= 89°C, ESI MS(m/z)= 421(M+H); IR(KBr, Cm-1): 3440.1, 2953.6, 2858.6, 2807.4, 2689.8, 1556.0, 1590.3, 1485.7, 1437.4, 1394.3, 1369.8, 1310.1, 1252.3, 1113.2, 1058.5, 585.8, 799.7, 777.7; Ή (300MHz, CDC13): 6=7.93(d, J=7.9 Hz, 2H, ArH), 7.54-7.39(m, 6H, ArH), 7.30 (d, J=8.1 Hz, 1H, ArH), 7.15(d, J=8.0 Hz, 2H, ArH), 4.19(t, J=6.3 Hz, 2H, OCH2), 3.70-3.60(m, 4H, OCH2), 2.44(s, 3H, SCH3), 2.30-2.15(m, 6H, NCH2), 1.26(m, 2H, CH2). Analysis calculated for C25H28 202S: C, 71.40; H, 6.71; N, 6.66. found: C, 71.38; H, 6.69; N, 6.64.
EXAMPLE 34: Synthesis of (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-3-(4-methylpiperidin-l-yl)propyl oxime oxalate (Compound 7c).
Figure imgf000049_0002
Into a 50 ml round bottom flask, 4-(methylthiophenyl)(naphthalen-l -yl)methanone O-3-chloropropyl oxime (1 mmole, 369 mg), 4-methylpiperidine (5 mmole, 0.59 ml) and dry methanol (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, methanol was evaporated under reduced pressure. The resulting mixture was poured onto water and extracted with ethyl acetate (3x50 ml), washed with water, dried over anhydrous Na?SC>4 and concentrated. The crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (350mg, 81.1%).The product obtained was oily so a salt of the compound was prepared.
Procedure for oxalate salt formation: Oxalic acid, 1 mmole/ 1 mmole of compound, (102.1 mg) and oily product (350 mg) were dissolved in dry methanol separately into two round bottom flasks The acid and the compound were mixed and shaken thoroughly. The salt was precipitated using dry diethyl ether, filtered, washed with the same and collected. Yield: 400 mg, 71.7%.
M.P.(oxalate salt of compound): 145° C, ESI MS(m/z)= 433 (M+H), IR Spectra: ( Br, Cm'1): 3445.4, 2928.8, 1648.1, 1451.6, 1246.1, 779.6. Ή NMR (300MHz, CDC13): 5=7.93(d, J=8.0 Hz, 2H, ArH), 7.56-7.38(m, 6H, ArH), 7.30(d, J=8.1 Ηζ,Ι Η, ArH), 7.16(d, J=8.5 Hz, 2H, ArH), 4.13(m, 2H, OCH2), 3.49-3.42(m, 2H, NCH2), 2.63(m, 2H, NCH2), 2.45(s, 3H, SCH3), 2.00(m, 2H, NCH2), 1.63(m, 5H, CH2 & CH), 1.24(m, 2H, CH2), 0.96(d, J=5.6 Hz, 3H, CHCH3). Analysis calculated for C27H32N2OS (free base): C, 74.96; H, 7.46; N, 6.48; found: C, 74.92; H, 7.43; N, 6.47.
Example 35: Synthesis of (4-(methyIthio)phenyl)(naphthalen-l-yl)methanone 0-3-(butyl(methyl)amino)propyI oxime (Compound 7d).
Figure imgf000050_0001
Into a 50 ml round bottom flask, (4-(methylthio)phenyl)(naphthalen-l-yl)methanone O-3-chloropropyl oxime (1 mmole, 369 mg), N-methylbutan-1 -amine (5 mmole, 0.59ml) and dry methanol (15.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, methanol was evaporated under reduced pressure. The resulting mixture was poured onto water and extracted with ethyl acetate (3x50 ml), washed with water, dried over anhydrous Na2S04 and concentrated. The crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (287mg, 68.3%). Oily Compound; ESI MS (m z)= 421 (M+H); Ή NMR (300MHz, CDC13): δ= 7.93(d, J=8 Hz, 2H, ArH), 7.62-7.39(m, 6H, ArH), 7.31-7.26(m, 1H, ArH), 7.15- 7.1 l(m, 2H, ArH), 4.19-4.10(m, 2H, OCH2), 2.46(s, 3H, SCH3), 2.44(t, J=6.7 Hz, 4H, NCH2), 2.24(s, 3H, NCH2), 1.34-1.22(m, 6H, CH2), 0.91(t, J=6.9 Hz, 3H, CH3). Analysis calculated for C26H32N2OS: C, 74.24; H, 7.67; N, 6.66; found: C, 74.22; H, 7.65; N, 6.63.
Example 36: Synthesis of (4-methoxyphenyI)(naphthaIen-l-yl)methanone 0-3- (2-ethylhexylamino)propyl oxime (Compound 7e).
Figure imgf000051_0001
Into a 50 ml round bottom flask, (4-Methoxy-phenyl)-naphthalen-l-yl-methanone 0-(3-chloro-propyl)-oxime (1 mmole, 353 mg), 2-ethylhexan-l -amine (5 mmole, 0.82ml) and dry methanol (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, methanol was evaporated under reduced pressure. The resulting mixture was poured onto water and extracted with ethyl acetate (3x50 ml), washed with water, dried over anhydrous Na2S04 and concentrated. The crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (321mg, 71.9%).
Oily Compound; ESI MS (m/z)= 447 (M+H); Ή NMR (300MHz, CDC13): δ= 8.07(d, J=9 Hz, 1H, ArH), 7.94-7.91(m, 1H, ArH), 7.67-7.61(m, 2H, ArH), 7.59- 7.54(m, 3H, ArH), 7.48-7.45 (m, 1H, ArH), 7.41-7.39 (d, 1H, ArH), 7.25-7.22(d, 2H, ArH), 3.48-3.28(m, 1H, OCH2), 3.25-3.23 (m, 1H, OCH2), 2.47 (s, 3H, SCH3), 1.93-1.87 (m, 2H, NCH2), l.50-1.48(m, 2H, NCH2), 1.12-0.92(m, 5H, CH2-CH2, CH), 0.81-0.60(m,12H, 3CH2, 2CH3); Analysis calculated for C29H38N202: C, 77.99; H, 8.58; N, 6.27; found: C, 78.03; H, 8.61; N, 6.30.
Example 37: Synthesis of (4-(methylthio)phenyl)(naphthalen-l-yI)methanone 0-4-(piperidin-l-yl)butyI oxime (Compound 8a).
Figure imgf000052_0001
Into a 50 ml round bottom flask, 4-(methylthiophenyl)(naphthalen-l-yl)methanone O-4-chlorobutyl oxime (1 mmole, 383 mg), piperidine (5 mmole, 0.49 ml) and dry methanol (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 7 hours. The reaction was followed by TLC monitoring. After completion of the reaction, methanol was evaporated under reduced pressure. The resulting mixture was poured onto water and extracted with ethyl acetate (3x50 ml), washed with water, dried over anhydrous Na S04 and concentrated. The crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product. Yield: 361 mg, 83.6%.
Oily Compound, ESI MS (m/z)= 433 (M+H); IR Spectra: (Neat, Cm"1): 3020.7, 2934.8, 1595.0, 1216.0, 761.4; Ή NMR (CDC13> 300MHz): 5=7.93 (d, J=8.04 Hz, 2 H, ArH), 7.67 (d, J=8.6 Hz, 1H, ArH), 7.58-7.41(m, 5H, ArH), 7.39-7.28(m, 1H, ArH), 7.17(d, J=8.6 Hz, 2H, ArH), 4.17-4.13(t, J=6.8 Hz, 2H, OC¾), 2.46(s, 3H, SCH3), 2.24-2.16(m, 6H, NCH2), 1.64-1.28(m, 10H, CH2); Analysis calculated for C27H32N2OS(free base) = C, 74.96; H, 7.46; N, 6.48; found: C, 74.92; H, 7.51; N, 6.50.
Example 38: Synthesis of (4-(methyltmo)phenyl)(naphthalen-l-yl)rnethanone 0-4-(pyrrolidin-l-yl)butyl oxime (Compound 8b).
Figure imgf000053_0001
Into a 50 ml round bottom flask, 4-(methylthio)phenyl)(naphthalen-l-yl)methanone O-3-chloropropyl oxime (1 mmole, 369 mg), Pyrrolidine (5 mmole, 0.42ml) and dry methanol (10.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 7 hours. The reaction was followed by TLC monitoring. After completion of the reaction, methanol was evaporated under reduced pressure. The resulting mixture was poured onto water and extracted with ethyl acetate (3 50 ml), washed with water, dried over anhydrous Na2S04 and concentrated. The crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (289mg, 69.1%).
Oily Compound; ESI MS(m/z)= 419(M+H); I (Neat, Cm-'): 3379.8, 3020.8, 1635.5, 1514.8, 1216.4, 761.7; 1H NMR (300MHz, CDC13): 5=7.93(d, J=8.1 Hz, 2H, ArH), 7.56-7.42(m, 6H, ArH), 7.33-7.28(m, 1H, ArH), 7.16(d, J=8.6 Hz, 2H, ArH), 4. 18(t, J=6.5 Hz, 2H, OCH2), 2.46(s, 3H, SCH3), 2.37-2.31(m, 4H, NCH2), 1.77-1.43(m, 8H, CH2). Analysis calculated for C26H3oN2OS: C, 74.60; H, 7.22; N, 6.69; found: C, 74.55; H, 7.18; N, 6.67.
Example 39: Synthesis of (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-4-(phenethylamino)butyl oxime (Compound 8c).
Figure imgf000053_0002
Into a 50 ml round bottom flask, 4-(methylthio)phenyl)(naphthalen-l-yl)methanone O-4-chlorobutyl oxime (1 mmole, 383 mg), 2-phenylethanamine (5 mmole, 0.63ml) and dry methanol (15.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 6 hours. The reaction was followed by TLC monitoring. After completion of the reaction, methanol was evaporated under reduced pressure. The resulting mixture was poured onto water and extracted with ethyl acetate (3x50 ml), washed with water, dried over anhydrous Na2SC>4 and concentrated. The crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (329mg, 72.5%).
Oily Compound; ESI MS (m/z)= 455 (M+H); Ή NMR (300MHz, CDC13): δ= 7.90- 7.85(m, 2H, ArH), 7.63(d, J=9 Hz, 1H, ArH), 7.54-7.49(m, 2H, ArH), 7.45-7.36(m, 5H, ArH), 7.29(m, 1H, ArH), 7.23-7.14(m, 5H, ArH), 4.13(t, J=6 Hz, 2H, OCH2), 2.50-2.45(m, 2H, NCH2), 2.45(s, 3H, SCH3), 1.60-1.55(m, 4H, NCH2, ArCH2), 0.91-0.85(m, 4H, CH2-CH2). Analysis calculated for 9H30N2OS: C, 76.61; H, 6.65; N, 6.16; found: C, 76.56; H, 6.64; N, 6.15.
EXAMPLE 40: Synthesis of (4-(methylthio)phenyl)(naphthalen-l-yl) methanone 0-4-(benzyl(ethyl)amino)butyl oxime (Compound 8d)
Figure imgf000054_0001
Into a 50 ml round bottom flask, 4-(methylthio)phenyl)(naphthalen-l-yl)methanone O-4-chlorobutyl oxime ( 1 mmole, 383 mg), N-benzylethanamine (5 mmole) and dry methanol (15.0 ml) were taken. The reaction mixture was refluxed under anhydrous conditions for 7 hours. The reaction was followed by TLC monitoring. After completion of the reaction, methanol was evaporated under reduced pressure. The resulting mixture was poured onto water and extracted with ethyl acetate (3x50 ml), washed with water, dried over anhydrous Na2S04 and concentrated. The crude product was purified by basic alumina column chromatography using distilled Hexane to yield the pure product (329mg, 72.5%). Oily Compound; ESI MS (m/z)= 483 (M+H); 1H NMR (300MHz, CDC13): δ= 7.93-7.91(m, 3H, ArH), 7.64-7.14(m, 13H, ArH), 4.17(t, J=6 Hz, 2H, OCH2), 3.82(s, 2H, NCH2), 2.75(q, J=4.0 Hz, 2H, NCH2), 2.54-2.47(m, 5H, SCH3, NCH2), 1.77-1.66(m, 4H, CH2), 1.19-1.14(t, J=4.0 Hz, 3H, CH3). Analysis calculated for C3iH3 N2OS: C, 77.14; H, 7.10; N, 5.80; found: C, 77.17; H, 7.12; N, 5.85.
Primary Evaluation of Aryl naphthyl methanone oxime derivative compounds in Leukemia cell lines K562 and HL-60
All the compounds synthesized were screened for cytotoxicity on leukemia cell lines K562, HL-60 and mouse fibroblast cell line NIH3T3 using (3 -(4.5-dimethylthiazol- 2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay kit from Sigma according to manufacturer's instructions and trypan blue exclusion method. Activity of these compounds is given in Table- 1. Cytotoxicity of five most active compounds (5a, 5d, 5j, 5m and 7c) was further checked in Kasumil and U937 cells. Compounds 5a, 5d, 5m and 7c exhibited higher efficacy than imatinib (IC50 values are shown in Table 2) in K562.
Table-1: IC50 (μΜ) values of compounds in K562, HL60 and NIH3T3 cell lines as tested using MTT assay after 48h treatment. Results were calculated from three independent experiments performed in triplicate. Compounds with IC50 more than 15μΜ were considered inactive.
Figure imgf000055_0001
Figure imgf000056_0001
34 8d 16.3 μΜ > 50 μΜ > 50 μΜ
Evaluation of hit compounds in multiple leukemia cell-lines:
To consider a molecule as a candidate compound in cancer drug therapy, the test compound must have specific cytotoxicity towards the cancer cells without affecting normal cell growth. Therefore, all active compounds were assessed for toxicity in non-cancer cell-lines: mouse fibroblast cell line (NIH3T3) and monkey kidney epithelial cells (Vero). 5d and 5m exhibited much higher IC50 values in the normal cells compared to leukemia cells. Therefore, based on safety index (IC50/CC50), 5d [Centans; based on IUPAC name prefixed with Central Drug Research Institute's signature (Cent)] was selected as a lead compound.
Table 2: ICso of Active compounds in Leukemia and normal cell lines. Results were calculated from three independent experiments performed in triplicates.
Figure imgf000057_0001
As described in table 2, among all the compounds tested compound 5d (Centans) showed strong cytotoxicity against BCR-ABL-positive CML model K562, acute myeloblastic leukemia model HL60, Kasumil (Acute Myeloid Leukemia with t(8;21) translocation) and U937 (monoblast), while it showed no toxicity against non-cancerous fibroblastic cell-lines Vero and NIH3T3. ND; not done. Evaluation of the efficacy of lead compound Centans in comparison with imatinib and dasatinib:
The efficacy of Centans in comparison to marketed drugs imatinib and dasatinib were determined in K562 and HL-60 cells that were used as examples of CML and AML respectively. As shown in table 3, Centans exhibited a much lower IC50 in comparison to both imatinib and dasatinib, indicating its higher efficacy.
Table 3:. IC50 of Centans, imatinib and dasatinib in K562 and HL60 cell lines after 48h of treatment. Following 48h treatment of indicated cell lines with Centans, imatinib or dasatinib (10 point dose response) MTT assays were performed and IC- 50 for the compounds were determined. Results were calculated from three independent experiments performed in triplicates.
Figure imgf000058_0001
Centans shows higher efficacy than imatinib and dasatinib in peripheral blood mononuclear cells (PBMC) isolated from CML patients. Next PBMCs isolated from freshly diagnosed, imatinib sensitive, imatinib resistant CML (BCR-ABL +ve) patient samples or healthy controls were treated for 48h with Centans, imatinib and dasatinib and following treatment the efficacy of each drug in each group was determined by MTT assay. As shown in Table 4. Centans showed most robust cytotoxic effect in PBMCs from imatinib-resistant CML patients (72%) compared to imatinib (40%) and dasatinib (59%). Centans also showed higher cytotoxicity than imatinib or dasatinib in PBMCs from freshly diagnosed or imatinib sensitive patients, while all three drugs showed comparative activity on PBMCs from healthy controls.
Table 4:. PBMCs isolated from indicated groups of BCR-ABL-positive CML patients or healthy individuals were treated with 1 μΜ Centans, imatinib or dasatinib for 48h and the cytotoxicity was determined by MTT assay in triplicates. Data represents % cell death. Centans showed better efficacy than both imatinib and dasatinib in all the groups, but this efficacy was highest in imatinib-resistant patient samples (p< 0.01).
Figure imgf000059_0001
Pl l 55.61 49.51 32.75
P15 71.19 64.1 52.79
Average 67.235 57.1325 46.1475
SEM 3.982484 3.42554 5.138736
Imatinib P2 69.46 32.81 56.61 Resistant 0.007977 0.0074
P13 70.03 34.05 53.82
P14 77.68 48.35 68.84
P17 78.93 47.84 56.41
P18 64.49 36.67 57.84
Average 72.118 39.944 58.704
SEM 3.030576 3.786158 2.926022
Imatinib P3 50.92 49.79 73.22 treated
/Responder 0.32157 0.510364
P12 62.41 48.39 43.65
P16 76.59 62.39 47.26
Average 63.30667 53.52333 54.71
SEM 6.429235 3.855299 8.065716
Next, comparative cytotoxic efficacy of centans with imatinib and dasatinib was
assessed in CML patient samples harbouring different BCR-ABL mutations by MTT
assay. PBMCs isolated from patients harbouring indicated mutations in BCR-ABL
were treated with 5μΜ centans, imatinib or dasatinib for 48h, followed by MTT
assay. As shown in Table 5. Centans showed much stronger cytotoxic activity in
comparison to imatinib or dasatinib. Importantly centans showed appreciable cytotoxicity in patient sample harbouring multidrug resistant T315I BCR-ABL mutation.
Table 5:. Centans induces cell death in PBMCs from patients with BCR-ABL mutations including multi-drug resistant T315I mutation with higher efficacy than imatinib and dasatinib.
Figure imgf000061_0001
Centans-induced cell-death in K562 and HL-60 is apoptotic in nature.
To determine whether cell death caused by Centans is specifically associated with apoptosis: phosphatidylserine exposure (Annexine V/ PI; Flow cytometry) was performed in K562 and HL-60 cell-lines. As apparent form Figure 1 , treatment with Centans caused a robust and dose-dependent increase in phosphatidylserine exposure, which reached 5 fold over vehicle with 5μΜ ANS in K562 and about 3 fold in HL-60.
Fig 1 Centans induces Apoptosis in K562 and HL-60 cells. (A and B) Centans increases phosphatidylserine exposure- K562(A) and HL-60 (B) cells were treated with vehicle (DMSO) or Centans (dissolved in DMSO) at indicated concentrations for 24 h and phosphatidylserine exposure was assessed by flow cytometry using the FLl-H channel (Annexin-V) and FL2-H channel (PI). Representative dot plots and relative apoptotic cell in the graph are shown. C and D is the graphical representation of data pooled from three independent experiments. *P < 0.05, **P < 0.01 ***P<0.001 compared to vehicle treated control. Centans induces G0/G1 growth arrest in K562 and HL-60 cells.
To evaluate the cytostatic effect of Centans, K562 and HL-60 cells were analysed for cell cycle progression in presence of Centans in and as shown in Fig. 2 A and B, that the Gl and apoptotic sub-populations were significantly increased by Centans treatment. To further confirm this, mRNA levels of cell cycle regulatory proteins p21, p27 and cyclin Dl were measured by real time PCR and we found that Centans significantly enhanced mRNA levels of growth suppressant proteins p21 and p27 while it decreased the level of pro-proliferative Cyclin Dl mRNA in both K562 and HL-60 cells. (Fig 2 C and D).
Fig 2 Centans induces Gl Growth arrest. (A and B) Cell cycle analysis - Propidium iodide (PI) staining of K562 cells (A) and HL-60 cells (B) treated with vehicle (DMSO) or 0.5 μΜ Centans, followed by flow cytometry analysis to find % distribution of cells in different phases of the cell cycle. Data has been shown as percent of total cells from data pooled from three independent experiments. (C and D). mRNA expression of cell cycle regulatory factors- 562(C) or HL-60 (D) cells were treated with Vehicle or Centans, followed by mRNA isolation and cDNA preparation and quantitative real-time PCR (p21, p27 and cyclin Dl). Graphs reprented pooled data from three independent experiments. *P < 0.05, **P < 0.01,***P < 0.001 compared to vehicle treated control.
Centans induces dephosphorylation of BCR-ABL and SRC:
Kinase activity of Bcr-Abl is the major cause of CML, and since Centans causes growth arrest and apoptosis in Bcr-Abl positive K562 cells, phosphorylation status of Bcr-Abl which is representative of its kinase activity was measured by immunoblotting. As shown in Fig 3 both imatinib and Centans dose dependently inhibited phosphorylation of BCR-ABL (pBCR-ABL) and its downstream substrates stat5 and Crkl, while eIF4E (used as a control gene unaffected by BCR-ABL signalling) remained unchanged.
Effect of Centans was also observed in terms of SRC kinase activation. SRC kinases activated by BCR-ABL remain fully active in imatinib-treated mouse leukemic cells, suggesting that imatinib does not inactivate all BCR-ABL activated signalling pathways. This SRC pathway is responsible for survival of leukemic cells that becomes imatinib resistant and for CML transition to lymphoid blast crisis. Effect of Centans and Imatinib was compared on its dephosphorylation by immunoblotting and we found that Centans dephosphorylating SRC-1 in a dose dependent manner, while imatinib failed to do so (Fig. 3).
Fig. 3. Centans inhibits BCR-ABL signalling and SRC phosphorylation. K562 Cells were treated with V (DMSO), 0.5μΜ, 1 μΜ Centans or 1 μΜ Imatinib for 48h and protein lysate prepared from these cells were used to detect the phosphorylation status of BCR-ABL, STAT-5, CRKL and vSRC-1 by western blotting. ELF4E and β-actin were used as loading control.
Centans Causes Differentiation in K562 cells:
In order to clarify whether the inhibitory effects of Centans on the growth and cell cycle of K562 cells was followed by differentiation, Centans treated cells was stained with Wright- Giemsa stain. Figure 4.A. clearly indicates that Centans is capable of inducing differentiation in K562 cells in a dose-dependent manner. After 3 day of incubation with 0.5 μΜ of Centans, cells exhibited megakaryocyte morphology characterized by a sharp increase in nuclear-to-cytoplasm ratio, and multiple lobed nuclei, while the vehicle-treated cells displayed homogenous population of immature blast-like cell morphology (Fig. 4. A). This differentiation was much more pronounced at 12d, where mature megakaryocytes were visible (Fig. 4A). Confirmation of Centans-mediated megakaryocytic differentiation was attained through measurement of expression of relevant cell differentiation markers by quantitative real time PCR. mRNA expression levels of cluster of differentiation 10 (CD 10) (transiently present during B-cell maturation at early-B and pre-B lymphoblastic stages and related to megakaryocytic differentiation), CD36 (erythroid differentiation lineage), GATA2 (Over expression of GATA-2 inhibits erythroid and promotes megakaryocyte differentiation) and CD61 (megakaryocytic differentiation marker) was measured. We found that the expression level of CD 10, GATA2 and CD61 were increased while that of CD36 was decreased. These results further confirm that the differentiation induced by Centans is megakaryocytic (Fig 4.B). Fi 4. CentANS induces Differentiation in K562 cells. (A) Giemsa Staining- K562 cells treated with CentANS (0.5μΜ) for 3, 6 and 12 days and were cytospinned on Microscopy slides and stained with Giemsa and May Grunwald solutions, slides were micro-photographed and used to detect change in nuclear morphology. (B) Expression of differentiation Markers - 562 cells were treated with vehicle; V (DMSO) or centANS and mRNA from these cells were isolated and reverse transcribed. cDNA was used to measure the expression CD 10, GATA2, CD61, (megakaryocytic lineage markers) and CD36 (Erythroid lineage marker) by Quantitative Real time PCR, GAPDH was used as control. Data represents mean ± SEM from three independent experiments; *P < 0.05, **P < 0.01, and ***P < 0.001 compared to control.
Centans induces granulocytic/monocytic differentiation in HL-60:
Differentiation potential of Centans on HL-60 cells was evaluated by the effect of this compound on Nuclear/cytosolic ratio and change in nuclear morphology, which are reliable markers of differentiation. For this, HL60 cell treated with Centans were cyto-spinned on microscope slides and stained with Wright- Giemsa and micro- photographed. As shown in Fig. 5A (upper panel), morphological features of differentiation, such as condensation of nuclei and protrusion of cytoplasm, were clearly evident among the treated cells. This was further confirmed by nitro blue tetrazolium (NBT) reduction assay in HL-60 cells (NBT reduction is a hallmark of monocyte activity). Fig. 5A (lower panel) depicts time-dependent reduction of NBT by Centans-treated cells.
Further confirm of granulocytic/monocytic differentiation of HL-60 cells by Centans, was obtained by QRT-PCR analysis of expression of lineage specific differentiation markers following Centans treatment. mRNA level of CDl lb, a marker for granulocytic differentiation was significantly increased (Fig. 5B). Further, mRNA level of GCSFR, a key marker for terminal granulocytic differentiation increased upon Centans treatment (Fig. 5B). Centans also enhanced expression of c/EBP group of transcription factors that have been shown to be especially critical in granulocyte development (Fig. 5B).
Figure 5. Centans induces granulocytic/monocytic differentiation in HL-60 model of AML. A. HL60 cells treated with Centans (l uM) for 3,6 and 12 days were cytospinned on Microscope slides and stained with Giemsa and May Griinwald solutions (upper panel) or NBT (lower panel), slides were microphotographed and used to detect change in nuclear morphology and NBT reduction. B. HL60 cells were treated with Vehicle (DMSO) or Centans as indicated in image, mRNA from these samples were isolated and reverse transcribed and these samples were used to measure the expression of CD1 lb GCSFR,and ΟΈΒΡα/β& ε by Quantitative realtime PCR, using GAPDH as normalizing control. Data presented as mean ± SEM from three independent experiments; *P < 0.05, **P < 0.01, and ***P < 0.001 compared to vehicle treated control.
Evaluation of Centans in solid tumor:
Efficacy of Centans and related series of compounds were evaluated in solid tumor cell-lines MCF-7 (estrogen receptor positive, non-metastatic breast tumor), MDA- MB-231 (estrogen receptor negative, metastatic breast tumor), DU-145 (prostrate tumor), Ishikawa (endometrial adenocarcinoma) cells by MTT assay following 24h treatment of indicated compounds. As depicted in table 6. Centans showed selective cytotoxicity in all the cancer cells tested but not in non-cancer cell-lines Vero and HEK-293. Efficacy of Centans was comparable to that of the positive control compound 4-hydroxy-tamoxifen (4-OHT).
Table 6. IC50 of Centans and related compounds in cell line models of breast, prostate and endometrial cancers after 48h of treatment. Following 48h treatment of indicated cell lines with Centans, Centans analogs or 4-OHT (10 point dose response) MTT assays were performed and IC-50 for the compounds were determined. Results were calculated from three independent experiments performed in triplicates. Compound MCF-7 MDA-MB231 DU-145 Ishikawa
4a 18 20 >50 >50
5a 13.5 8.8 10 10
5b 6.6 5.01 9.5 6
5c 14 12.78 15 9
5d (Centans) 7.5 7.2 9 12
5f >50 >50 >50 >50
5m 8 7.2 9.5 7
6a 18 >50 >50 >50
6b 25 >50 >50 >50
6c 15 >50 >50 >50
6d 20 >50 >50 >50
6e 23 >50 >50 >50
6i 20.5 >50 >50 >50
7a 5 20 15 12
7b >50 >50 >50 >50
7c 6.5 20 10 >50
8a 8 18 7.5 18
8b >50 >50 >50 >50
OH-TAM 8.8 8 10 20
Efficacy of centans in colon cancer cell-lines were also assessed using sulphorhodamine B assay and as shown in table 7, centans exhibited robust cytotoxicity in four different colon cancer cell lines compared to the marketted drug for colon cancer 5-fluoro uracil (5-FU). Table 7. IC50 of Centans in colon cancer cell lines as determined Sulphorhodamine B (SRB) assay.
Figure imgf000067_0001
Centans induces apoptosis in MCF-7 and MDA-MB-231 cell-lines.
To asses if the cell death induced by centans in MCF-7 and MDA-MB231 lines is apoptotic in nature, apoptosis was measured by flow cytometry using annexin V PI staining kit from Sigma according to manufacturer's instructions. A concentration- dependent increase in apoptotic cell population was observed upon treatment with Centans and the effect was stronger in MDA-MB231 than MCF-7 cells (Fig 6A and B).
Fig.6 Apoptosis induction by Centans in breast cancer cells. Annexin V/PI staining of (A) MCF-7 and (B) MDA-MB231 cells were treated with vehicle (DMSO) or Centans at indicated concentrations for 24 h and DNA fragmentation was assessed by flow cytometry using the FLl-H channel (Annexin-V) and FL2-H channel (PI) of a Becton Dickinson FACS Calibur. Shown are representative dot plots. Quantification of flow cytometry data shown as percent of total cells (right panel). Data presented as mean ± SEM from three independent experiments; *P < 0.05, **P < 0.01, and "*P<0.001 compared to control.
Centans inhibits EGFR and Her2 phosphorylation
Since EGFR and Her2 play major roles in breast cancer development and metastatis, the effect of Centans on regulation of these two factors was evaluated in MCF-7 and MDA-MB-231 cells by enzyme-linked immunosorbant assays (ELISA). As depicted in fig. 7. A and B, EGF dependent EGFR phosphorylation at Tyr1068 was strongly attenuated by Centans in both MCF-7 and MDA-MB-231 cells and this effect was much stronger than that of Gefitinib (marketted EGFR inhibitor/ anti-cancer drug). The calculated IC50 for Centans in terms of EGFR phosphorylation were 14.7nM (MCF-7) and 12.75nM (MDA-MB-231). Centans treatment also significantly reduced HER2 phosphorylation in a dose-dependent manner in both MCF-7 and MDA-MB-231 cells (Fig. 7C and D).
Fig. 7. Inhibition of EGFR and Her2 phosphorylation by Centans in MCF-7 and MDA-MB231 cells. Serum starved (A,C) MCF-7 cells and (B,D) MDA-MB231 cells were pre-incubated for 1 h with the indicated concentrations of Centans prior to stimulation with EGF for 15 min and EGFR (A and B) or Her2 (C and D) phosphorylation were measured by ELISA. Gef=Gefitinib. All doses are in μΜ.
Centans reduces tumor volume in mouse xenograft model:
The effect of Centans on the growth of MCF-7 xenograft tumor was studied. Injection of MCF-7 cells in the peritoneal cavity of NIH-III strain of nude mice resulted in the appearance of palpable tumors that rapidly grew from 9 d to 25 d. Beyond 25 d, vehicle treated mice bearing tumors (control) show significant mortality (data not shown). Administration of Centans at lemg-kg^day*1 dose resulted in nearly 50% reduction in relative tumor volume compared to vehicle treated mice on days 21 and 25 following the inoculation of MCF-7 cells (Fig 8A).
Histological assessment showed that tumors from vehicle-treated mice were primarily composed of tumor epithelial cells with small amounts of mouse-derived stroma and frequent blood vessels. Tumors from mice treated with Centans presented with large areas of stroma where deletion of epithelial cells had occurred as evident from few mitotic figures (Fig 8B). In addition, a significant reduction in the levels of PCNA (marker of proliferation) was observed in tumors from Centans treated mice compared to control (Fig 8C).
Fig.8 Regression of xenograft tumor by Centans in athymic nude mice. (A) Increase in relative tumor volume over time in various treatment groups indicated. N = 10 mice/group; data represent mean ± S.E.M. *P < 0.05 and **P < 0.01 compared to vehicle (carboxymethyl cellulose). (B) Effect of Centans treatment on tumor morphology. Representative tumor sections from mice treated with vehicle or Centans (lemg.kg ' .day"') for 25 days. (C) Effect of Centans treatment on PCNA levels were analyzed by Western blotting from in tumors of vehicle or Centans treated mice. Data represent mean ± S.E.M. **P < 0.01 compared to vehicle-treated control.
Centans reduces CD133+ colon cancer stem cells
Since centans showed cytotoxicity in drug resistant leukemic cells, the efficacy of centans in cancer stem cells (CD133+ DLD1 colon cancer cells) was assessed. As shown in Fig. 9. In vehicle (DMSO) treated control cells 15.30% cells were found to be CD133+ (value represents %CD133+ cells minus % cells in isotype control) and 24h treatment with 20uM centans reduced this population to 2.94% (5.79-2.85), while salinomycin the positive control at equivalent concentration reduced the CD 133+ population to 5.42% (5.91-0.49) and 5-FU had no effect.
Fig. 9. Centans reduces CD 133+ colon cancer stem cells with a higher efficacy than salinomycin. DLD1 colon cancer cells were treated with indicated compounds for 24h following which the CD 133+ population was assessed by flow cytometry using CD 133 antibody or relevant isotype control antibody (BD biosciences) in a Becton Dickinson FACS Calibur. Numbers in the dot plot represent % CD 133+ cells.
ADVANTAGES OF THE PRESENT INVENTION
1. The present compound shows better efficacy than existing drugs imatinib and dasatinib both in leukemia cell-lines and patient samples.
2. The present compound causes robust apoptosis in imatinib resistant cancer samples.
3. The present compound induces cell death in broader range of leukemic cells than imatinib or dasatinib.
4. The present compound induces differentiation in blast cells which is indicative of restoring normal blood cell functions.
5. The present compound is also efficacious in solid tumor forming cell-lines including, breast, prostate and endometrial cancers.

Claims

We claim
1. A compound of formula I or a pharmaceutically acceptable salt thereof,
Figure imgf000070_0001
Formula I
R1= H, halogen, alkyl, alkoxy, nitro
R3 = H, halogen, alkyl, alkoxy, hydroxy, nitro
R3 = H, alkyl, alkoxy, nitro, halogen
X = 0, S
R4 = hydrogen, akyl group (ο alkylamino group |-ce), cyclic or open chain amines
Rs = hydrogen, alkyl group alkylepoxy.alkylhydroxyamino group
(ci-ce),alkylamlno group (ci -ce), cyclic or open chain amines.ester and amides derivatives
selected from the group consisting of
Figure imgf000070_0002
m = 1 , 2 , 3, 4 The compound as claimed in claim 1, wherein the compound is selected from group consisting of: :
1. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone oxime (4a),
2. (4-methoxyphenyl)(naphthalen- 1 -yl)methanone oxime (4b),
3. (4-hydroxyphenyl)(naphthalen-l-yl)methanone oxime (4c),
4. (4-(methylthio)phenyl)(naphthalen- l-yl)methanone 0-2-(piperidin- 1- yl)ethyl oxime oxalate (5a),
5. (4-(methylthio)phenyl)(naphthalen- l-yl)methanone 0-2-(pyrrolidin-l- yl)ethyl oxime oxalate (5b),
6. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2- (dimethylamino)ethyl oxime oxalate (5c),
7. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2- (diethylamino)ethyl oxime oxalate (5d),
8. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2- (diisopropylamino)ethyl oxime (5e),
9. (4-(methylthio)phenyl)(naphthalen- 1 -yl)methanone 0-2-moφholinoethyl oxime (5f).
10. (4-(methylthio)phenyl)(naphthalen- 1 -yl)methanone O- 1 - (dimethylamino)propan-2-yl oxime oxalate (5g),
1 1. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2-(azepan-l- yl)ethyl oxime oxalate (5h),
12. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2- (diethylamino)ethyl oxime citrate (5i),
13. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2- (diethylamino)ethyl oxime fumarate (5j),
14. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2- (diethylamino)ethyl oxime tartrate (5k),
15. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-2- (diethylamino)ethyl oxime (51),
16. (4-(methylthio)phenyl)(naphthalen- l-yl)methanone 0-3- (dimethylamino)propyl oxime oxalate (5m),
17. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone O-3-chloropropyl oxime (5n),
18. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone O-4-chlorobutyl oxime (5o),
1 . Ethyl 2-((4-(methylthio)phenyl)(naphthalen-l- yl)methyIeneaminooxy)acetate ( 5p),
20. N,N-diethyl-2-((4-(methylthio)phenyl)(naphthalen-l- yl)methyleneaminooxy) acetamide (5q),
21. (4-methoxyphenyl)(naphthalen- 1 -yl)methanone 0-2-(piperidin- 1 -yl)ethyl oxime oxalate (6a),
22. (4-methoxyphenyl)(naphthalen-l-yl)methanone 0-2-(pyrrolidin-l- yl)ethyl oxime oxalate (6b),
23. (4-methoxyphenyl)(naphthalen-l-yl)methanone 0-2- (dimethylamino)ethyl oxime oxalate (6c),
24. (4-methoxyphenyl)(naphthalen- 1 -yl)methanone 0-2-(diethylamino)ethyl oxime oxalate (6d),
25. (4-methoxyphenyl)(naphthalen-l-yl)methanone 0-2- (diisopropylamino)ethyl oxime oxalate (6e),
26. (4-methoxyphenyl)(naphthalen-l-yl)methanone 0-1- (dimethylamino)propan-2-yl oxime oxalate (6f),
27. (4-methoxyphenyl)(naphthalen- 1 -yl)methanone 0-2-(azepan- 1 -yl)ethyl oxime oxalate (6g),
28. (4-methoxyphenyl)(naphthalen- 1 -yl)methanone 0-2-mo holinoethyl oxime (6h),
29. (4-methoxyphenyl)(naphthalen-l-yl)methanone 0-3- (dimethylamino)propyl oxime oxalate (6i),
30. (4-methoxyphenyl)(naphthalen-l-yl)methanone O-3-chJoropropyl oxime (6j),
31. (4-methoxyphenyl)(naphthalen- 1 -yl)methanone 0-3 -(piperidin- 1 - yl)propyl oxime (6k),
32. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-3-(piperidin-l- yl)propyl oxime oxalate (7a),
33. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-3- morpholinopropyl oxime (7b),
34. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-3-(4- methylpiperidin-l-yl)propyl oxime oxalate (7c),
35. (4-(methylthio)phenyl) (naphthalen-l-yl)methanone 0-3- (butyl(methyl)amino) propyl oxime (7d),
36. (4-methoxyphenyl)(naphthalen-l-yl)methanone 0-3-(2- ethylhexylamino)propyl oxime (7e),
37. (4-(methyl thio)phenyl)(naphthalen- 1 -yl)methanone 0-4-(piperidin- 1 - yl)butyl oxime (8a),
38. (4-(methylthio)phenyl)(naphthalen- 1 -yl)methanone 0-4-(pyrrolidin- 1 - yl)butyl oxime (8b),
39. (4-(methylthio)phenyl)(naphthalen-l-yl)methanone 0-4- (phenethylamino)butyl oxime (8c),
40. (4-(methylthio)phenyl)(naphthalen- 1 -yl)methanoneO-4-(benzyl(ethyl) amino) butyl oxime (8d),
3. The compound as claimed in claim 1, wherein the structural formula of the compound is:
Figure imgf000074_0001
Figure imgf000074_0002
Figure imgf000074_0003
Figure imgf000074_0004
72
Figure imgf000075_0001
Figure imgf000075_0002
5
Figure imgf000075_0003
Figure imgf000075_0004
Figure imgf000075_0005
5f
Figure imgf000076_0001
Figure imgf000076_0002
Figure imgf000076_0003
Figure imgf000076_0004
Figure imgf000076_0005
74
Figure imgf000077_0001
Figure imgf000077_0002
5p,
Figure imgf000078_0001
Figure imgf000078_0002
Figure imgf000078_0003
Figure imgf000078_0004
Figure imgf000078_0005
76
Figure imgf000079_0001
Figure imgf000079_0002
Figure imgf000079_0003
Figure imgf000079_0004
Figure imgf000079_0005
77
Figure imgf000080_0001
Figure imgf000080_0002
Figure imgf000080_0003
Figure imgf000080_0004
Figure imgf000080_0005
78
Figure imgf000081_0001
Figure imgf000081_0002
Figure imgf000081_0003
Figure imgf000081_0004
Figure imgf000081_0005
79
Figure imgf000082_0001
4. The compound as claimed in claim 1, wherein the compound is for use in treating cancer and killing of drug resistant cancer stem cells.
5. The compound as claimed in claim 4, wherein the cancer is selected from the group consisting of blood cancer, leukemic cancer, lymphoma cancer and multiple myeloma cancer.
6. A process for the preparation of compound as claimed in claim 1, comprising the steps of;
a) reacting a substituted phenylnaphthalen-l-yl-methanone compound (3) of formula II
Figure imgf000082_0002
Form-fa.■
flanpoimd 3} * = H. kalogea. a-kyL a-fco-ty. -fco
R» = H. l-alogc--. afcyl a-fcaxy. hydroxy, tiro
R3= H. afcyl a Boxy, aitro. aafesea
X = O. S
R*= hydroge-k. a-_yt 0n>ap a_.iyfei.- gioap cycftcor open c-kai. with hydroxylamine hydrochloride and pyridine in absolute ethanol to form substituted phenylnaphthalen-l-yl-methanone oxime (4) of formula I
Figure imgf000083_0001
Foimiil
(compound 4)
R1 = H. altyi.
R* a H.
R*= H akotxy.
X =■ O. S
R*= a reacting a substituted phenylnaphthalen-l-yl-methanone oxime as obtained from step (a) with an aminoalkyl chloride, alkyl chloride, alkylepoxychloride, cyclic or open chain amino chloride, alkylhydroxyaminochloride, alkylacetachloride or dihaloalkane in the presence of a base at a reflux temperature in the range of 70°C to 120°C to form the compound 5, 6, 7 & 8 of formula I.
Figure imgf000083_0002
R1 = H. fcaiose-t. afcyl aftozy. aiho
R* = H. kuloflea. aatyt akaxy. hydroxy. afao
RJ= H. akyl aBtuy. rnHro. bafaoea
X = O. S
R* = a akyha iae snap (c, - caaaa
Figure imgf000084_0001
7. A process for the preparation of compound of general formula II, the said process comprising of reacting compound 3c (formula II) with hydroxylamine hydrochloride in the presence of a base like sodium acetate or pyridine and solvent used is absolute ethanol/methanol to furnish the compound 4c of formula I.
8. The process as claimed in claim 6, wherein the base is selected from the group consisting of K2C03, CsC03, KOH and NaH.
9. The process as claimed in claim 6, wherein the solvent is selected from the group consisting of dry DMF, acetone and THF.
10. The compound as claimed in claim 1, wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochlorides, citrates, oxalates,fumarates, malates and tartrates.
1 1. A pharmaceutical composition comprising an effective amount of a compound of formula I optionally along with a pharmaceutically acceptable carrier or diluents.
12. A method for treatment of cancer in a subject comprising, administring to a subject in need thereof an effective amount of compound of formula 1 as claimed in claim 1.
13. The method as claimed in claim 12, wherein the method is for use in the treatment of leukemia.
14. The method as claimed in claim 12, wherein the method is for use in the suppression of BCR-ABL activity in CML thereof.
15. The method as claimed in claim 12, wherein the method is for use in the suppression of c-SRC activity in imatinib-resistance in CML thereof.
16. The method as claimed in claim 12, wherein the method is for use in inducing apoptosis in imatinib-resistant CML cells.
17. The method as claimed in claim 12, wherein the method is for use in inducting apoptosis and differentiation in AML cells.
18. The method as claimed in claim 12, wherein the method is for use in inducting megakaryocytic differentiation in K562 cells and differentiation in blast cells of erythroleukemia or increasing platelet amount.
19. The method as claimed in claim 12, wherein the method is for use in exhibiting cancer-specific cytotoxicity in ER-positive or ER-negative breast cancer cells, prostate cancer cells and uternine adenocarcinoma.
PCT/IN2014/000556 2013-08-30 2014-08-29 Aryl naphthyl methanone oxime(s) and process for preparation thereof Ceased WO2015029068A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/915,194 US9994515B2 (en) 2013-08-30 2014-08-29 Aryl naphthyl methanone oxime(s) and process for preparation thereof
EP14786724.6A EP3039010B1 (en) 2013-08-30 2014-08-29 Aryl naphthyl methanone oxime(s) and process for preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2567DE2013 2013-08-30
IN2567/DEL/2013 2013-08-30

Publications (2)

Publication Number Publication Date
WO2015029068A1 true WO2015029068A1 (en) 2015-03-05
WO2015029068A4 WO2015029068A4 (en) 2015-06-11

Family

ID=51753267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000556 Ceased WO2015029068A1 (en) 2013-08-30 2014-08-29 Aryl naphthyl methanone oxime(s) and process for preparation thereof

Country Status (3)

Country Link
US (1) US9994515B2 (en)
EP (1) EP3039010B1 (en)
WO (1) WO2015029068A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070276036A1 (en) * 2004-07-26 2007-11-29 Gerd Dannhardt Non-Glycosidic and Non-Peptidic Select Inhibitors, and the Use Thereof
JP2012092328A (en) * 2010-09-30 2012-05-17 Dainippon Printing Co Ltd Base generator, photosensitive resin composition, pattern formation material comprising the photosensitive resin composition, and method for producing relief pattern and article using the composition
JP2012092329A (en) * 2010-09-30 2012-05-17 Dainippon Printing Co Ltd Base generator, photosensitive resin composition, pattern formation material comprising the photosensitive resin composition, and method for producing relief pattern and article using the composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673746A (en) * 1978-10-06 1987-06-16 Hoechst-Roussel Pharmaceuticals, Inc. 1,2-benzisoxazoloxyacetic acids and related compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070276036A1 (en) * 2004-07-26 2007-11-29 Gerd Dannhardt Non-Glycosidic and Non-Peptidic Select Inhibitors, and the Use Thereof
JP2012092328A (en) * 2010-09-30 2012-05-17 Dainippon Printing Co Ltd Base generator, photosensitive resin composition, pattern formation material comprising the photosensitive resin composition, and method for producing relief pattern and article using the composition
JP2012092329A (en) * 2010-09-30 2012-05-17 Dainippon Printing Co Ltd Base generator, photosensitive resin composition, pattern formation material comprising the photosensitive resin composition, and method for producing relief pattern and article using the composition

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
AARTS, M.; SHARPE, R.; GARCIA-MURILLAS, I.; GEVENSLEBEN, H.; HURD, M. S.; SHUMWAY, S. D.; TONIATTI, C.; ASHWORTH, A.; TURNER, N. C, CANCER DISCOV, vol. 2, no. 6, pages 524 - 39
AMSBERG, K.G.; BRUMMENDORF, T. H., EXPERT REV ANTICANCER THER, vol. 12, no. 9, 2012, pages 1121 - 1127
ATUL KUMAR; S. R. PATHAK; PERVEZ AHMAD; S. RAY; P. TEWARI; A. K. SRIVASTAVA, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, 2006, pages 2719 - 2723
BANDANA CHAKRAVARTI ET AL: "Thioaryl Naphthylmethanone Oxime Ether Analogs as Novel Anticancer Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 19, 9 October 2014 (2014-10-09), pages 8010 - 8025, XP055161332, ISSN: 0022-2623, DOI: 10.1021/jm500873e *
BOSE, P.; PERKINS, E. B.; HONEYCUT, C.; WELLONS, M. D.; STEFAN, T.; JACOBBERGER, J. W.; KONTOPODIS, E.; BEUMER, J. H.; EGORIN, M., CANCER CHEMOTHER PHARMACOL, vol. 69, no. 6, 2012, pages 1657 - 67
CORBIN, A.S.; AGARWAL, A.; LORIAUX, M.; CORTES, J.; DEININGER, M.W.; DRUKER, B.J., J CLIN INVEST., vol. 121, no. 1, 2011, pages 396 - 409
DAUD, A. I.; KRISHNAMURTHI, S. S.; SALEH, M. N.; GITLITZ, B. J.; BORAD, M. J.; GOLD, P. J.; CHIOREAN, E. G.; SPRINGETT, G. M.; ABB, CLIN CANCER RES, vol. 18, no. 4, 2011, pages 1092 - 1100
DEANGELO, D. J.; STONE, R. M.; HEANEY, M. L.; NIMER, S. D.; PAQUETTE, R. L.; KLISOVIC, R. B.; CALIGIURI, M. A.; COOPER, M. R.; LEC, BLOOD, vol. 108, no. 12, 2006, pages 3674 - 81
GOLDMAN, J. M.; MARIN, D., ONCOLOGY (WILLISTON PARK), vol. 26, no. 10, October 2012 (2012-10-01), pages 901 - 7
GUPTA, P.B.; ONDER, T.T.; JIANG, G.; TAO, K.; KUPERWASSER, C.; WEINBERG, R.A.; LANDER, E. S., CELL, vol. 138, no. 4, 2009, pages 645 - 59
HASINOFF, B. B.; WU, X.; NITISS, J. L.; KANAGASABAI, R.; YALOWICH, J. C., BIOCHEM PHARMACOL, vol. 84, no. 12, 2012, pages 1617 - 26
KUMAR A ET AL: "Novel 2-aryl-naphtho[1,2-d]oxazole derivatives as potential PTP-1B inhibitors showing antihyperglycemic activities", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 44, no. 1, 1 January 2009 (2009-01-01), pages 109 - 116, XP025842151, ISSN: 0223-5234, [retrieved on 20080327], DOI: 10.1016/J.EJMECH.2008.03.009 *
LAMBERT, J. D.; SANG, S.; YANG, C. S., CHEM RES TOXICOL, vol. 20, no. 4, 2007, pages 583 - 5
LEONARD, J. P.; LACASCE, A. S.; SMITH, M. R.; NOY, A.; CHIRIEAC, L. R.; RODIG, S. J.; YU, J. Q.; VALLABHAJOSULA, S.; SCHODER, H.;, BLOOD, vol. 119, no. 20, 2012, pages 4597 - 607
NESTAL DE MORAES, G.; SOUZA, P. S.; COSTAS, F. C.; VASCONCELOS, F. C.; REIS, F.R.; MAIA, R. C., LEUK RES TREATMENT., vol. 2012, 2012, pages 671702
O'BRIEN, C.A.; POLLETT, A.; GALLINGER, S.; DICK, J. E., NATURE, vol. 445, no. 7123, 2007, pages 106 - 10
O'HARE, T.; DEININGER, M.W.; EIDE, C.A.; CLACKSON, T.; DRUKER, B.J., CLIN CANCER RES., vol. 17, no. 2, 2011, pages 212 - 21
P. LEUK RES TREATMENT, 2012, pages 939021
PRICL, S.; FERMEGLIA, M.; FERRONE, M.; TAMBORINI, E., MOL CANCER THER., vol. 4, no. 8, 2005, pages 1167 - 74
QU, L.; TANG, X., CANCER CHEMOTHER PHARMACOL, vol. 65, no. 2, 2010, pages 201 - 5
SANTOS, F. P.; KANTARJIAN, H.; QUINTAS-CARDAMA, A.; CORTES, J., CANCER J, vol. 17, no. 6, 2011, pages 465 - 76
SAVICKIENE, J.; TREIGYTE, G.; BORUTINSKAITE, V. V.; NAVAKAUSKIENE, R., CELL MOL BIOL LETT, vol. 17, no. 4, 2012, pages 501 - 25
SOVERINI, S. ET AL., HAEMATOLOGICA., vol. 92, no. 3, March 2007 (2007-03-01), pages 401 - 4
SRIVASTAVA, N.; SANGITA; RAY, S.; SINGH, M. M.; DWIVEDI, A.; KUMAR, A., BIOORG MED CHEM, vol. 12, no. 5, 2004, pages 1011 - 21
WEISBERG, E.; MANLEY, P.W.; COWAN-JACOB, S.W.; HOCHHAUS, A.; GRIFFIN, J.D., NAT REV CANCER., vol. 7, no. 5, 2007, pages 345 - 56
ZINI, R.; NORFO, R.; FERRARI, F.; BIANCHI, E.; SALATI, S.; PENNUCCI, V.; SACCHI, G.; CARBONI, C.; CECCHERELLI, G. B.; TAGLIAFICO,, ECP HEMATOL, vol. 40, no. 12, 2012, pages 1043 - 1054

Also Published As

Publication number Publication date
WO2015029068A4 (en) 2015-06-11
US20160304442A1 (en) 2016-10-20
US9994515B2 (en) 2018-06-12
EP3039010B1 (en) 2017-10-11
EP3039010A1 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
JP2022088416A (en) Tetrahydro-pyrido [3,4-b] indole estrogen receptor modulator and its use
Kim et al. Bakuchiol suppresses proliferation of skin cancer cells by directly targeting Hck, Blk, and p38 MAP kinase
US9573899B2 (en) USP7 inhibitor compounds and methods of use
JP2022526266A (en) Compositions and Methods for Treating Cancer
Shi et al. Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista
Oh et al. JAK2 regulation by licochalcone H inhibits the cell growth and induces apoptosis in oral squamous cell carcinoma
JP7241134B2 (en) 2-benzoylaminobenzamide derivatives as BCL-3 inhibitors
KR20140109498A (en) Synthesis of Polyhydroxy Benzopyran Ketone Compound and Anti-Tumor Effect Thereof
KR20210027382A (en) Activator of the unfolded protein reaction
CA2898732A1 (en) Estrogen receptor inhibitors
Kumar et al. Alkyne–azide cycloaddition analogues of dehydrozingerone as potential anti-prostate cancer inhibitors via the PI3K/Akt/NF-kB pathway
MX2007014843A (en) Selective apoptotic induction in cancer cells including activation of procaspase-3.
Han et al. Discovery of β-cyclocitral-derived mono-carbonyl curcumin analogs as anti-hepatocellular carcinoma agents via suppression of MAPK signaling pathway
Li et al. Synthesis and discovery of 18β-glycyrrhetinic acid derivatives inhibiting cancer stem cell properties in ovarian cancer cells
US9994515B2 (en) Aryl naphthyl methanone oxime(s) and process for preparation thereof
CN114026098B (en) Benzopyranyl compounds, methods and uses
EP2833865A1 (en) Treatment of proliferative diseases with pyrimidodiazepinones
EP2909171B1 (en) N-substituted 3,4-bis(catechol)pyrrole compounds, their preparation and use in the treatment of cancer
US9604974B2 (en) Compounds as modulator of JAK-STAT pathway, methods and applications thereof
Gao et al. A novel amino-pyrimidine inhibitor suppresses tumor growth via microtubule destabilization and Bmi-1 down-regulation
Acheampong Novel hybrid analogs of Estrone origin exhibits cytotoxic effects against EGFR-dependent cancers
TW202523325A (en) Novel compound, pharmaceutical composition comprising the same and method for treating cancer using the same
Alhadad et al. Development of nimesulide analogues as dual tubulin and HSP27 inhibitor for treating female cancers
WO2025202991A1 (en) Crystalline form of (s)-n-ethyl-3-((9-ethyl-2-(((2r,3s)-2-hydroxypentan-3-yl)amino)-9h-purin-6-yl)amino)-pyrrolidine-1-sulfonamide
Ding et al. Design, Synthesis, and Biological Evaluation of Benzo [B] Thiophene 1, 1-Dioxide (BTP) Derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14786724

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
REEP Request for entry into the european phase

Ref document number: 2014786724

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14915194

Country of ref document: US

Ref document number: 2014786724

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016004289

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112016004289

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160226